Fall 12-18-2015

Development of Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) Methods to Study Pathophysiology Underlying Neurodegenerative Diseases in Murine Models

Aditya N. Bade
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd

Part of the Other Neuroscience and Neurobiology Commons

Recommended Citation
https://digitalcommons.unmc.edu/etd/53

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.
Development of Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) Methods to Study Pathophysiology Underlying Neurodegenerative Diseases in Murine Models

by

Aditya N. Bade

A DISSERTATION

Presented to the Faculty of

The Graduate College in the University of Nebraska

In Partial Fulfillment of the Requirements

For the Degree of Doctor of Philosophy

Pharmacology and Experimental Neuroscience

Under the Supervision of Professor Yutong Liu

University of Nebraska Medical Center

Omaha, Nebraska

December, 2014
# TABLE OF CONTENTS

TABLE OF CONTENTS.......................................................................................... I

LIST OF FIGURES ............................................................................................... VII

LIST OF TABLES .................................................................................................. IX

ACKNOWLEDGEMENTS ....................................................................................... X

ABSTRACT ........................................................................................................... XII

LIST OF ABBREVIATIONS ................................................................................... XV

## CHAPTER - 1: Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) ........... 1

1.1. Introduction ........................................................................................................ 2

1.2. MRI contrast agents ....................................................................................... 3

1.3. Paramagnetic contrast agents ........................................................................ 4

1.4. Mn\(^{2+}\) – a paramagnetic contrast agent ......................................................... 5

1.5. MEMRI ............................................................................................................. 5

1.6. Properties of Mn\(^{2+}\) in the CNS ...................................................................... 7

1.7. Entry of Mn\(^{2+}\) into the CNS ........................................................................... 8

1.8. Mn\(^{2+}\) - an intracellular contrast agent .......................................................... 8

1.9. Applications of MEMRI in experimental neuroscience ................................... 9

1.10. Methodological considerations for Mn\(^{2+}\) administration ........................... 10
1.10.1 Preparation of MnCl₂ solution: ................................................................. 10
1.10.2. Administration of Mn²⁺ ................................................................. 11
1.11. Mn²⁺ - a trace element and related toxicity ........................................... 13
1.12. MEMRI in Humans............................................................................. 16
1.13. Objective and aims of the thesis ........................................................ 17
  1.13.1. Objective ..................................................................................... 17
  1.13.2. Aims .......................................................................................... 17
1.14. References............................................................................................ 27

CHAPTER - 2: Role of Glia and Neurons in MEMRI Signal Enhancement During
Inflammation .................................................................................................. 35
2.1. Introduction ............................................................................................ 36
2.2. Materials and Methods........................................................................ 37
  2.2.1. PC-12 Differentiation .................................................................... 37
  2.2.3. Cell Co-culture and Activation ...................................................... 38
  2.2.4. Mouse Model of Acute Neuroinflammation .................................. 39
  2.2.5. MEMRI ....................................................................................... 39
  2.2.6. Immunohistology ........................................................................ 41
  2.2.7. Statistical Analysis ....................................................................... 42
2.3. Results .................................................................................................... 42
2.3.1. Mn$^{2+}$ Uptake by PC-12 Cells ................................................................. 42

2.3.2. Manganese Uptake by Glial Cells .......................................................... 44

2.3.3. MRI Signal Enhancement and Enhanced Volume Measurements .......... 44

2.3.4. Immunohistology .................................................................................. 45

2.4. Discussion ................................................................................................. 55

2.5. References ............................................................................................... 59

CHAPTER - 3: MEMRI Detects brain pathology in animal model of neurodegenerative Diseases .......................................................................................................... 66

3.1. Introduction ............................................................................................... 67

3.2. Materials and Methods ........................................................................... 68

3.2.1. Murine neuroAIDS model ..................................................................... 68

3.2.2. Viral load ............................................................................................... 69

3.2.3. Flow cytometry ..................................................................................... 70

3.2.4. Immunohistology .................................................................................. 70

3.2.5. MEMRI .................................................................................................. 72

3.2.6. MRI data pre-processing ..................................................................... 72

3.2.7. MEMRI signal enhancement and tissue manganese concentration ....... 73

3.2.8. MEMRI enhancement analysis .............................................................. 76

3.2.9. Brain structure volumetric analysis ....................................................... 77

3.2.10. Detection of Mn$^{2+}$ toxicity ............................................................... 77
3.3. Results ............................................................................................................... 77

3.3.1. HIV-1 Infection of humanized mice ................................................................. 77

3.3.2. Leukocyte brain infiltration ............................................................................. 78

3.3.3. MEMRI ......................................................................................................... 78

3.3.4. Immunohistology ............................................................................................ 80

3.4. Discussion .......................................................................................................... 97

3.5. References ......................................................................................................... 102

CHAPTER 4: Generation of a MEMRI-based NOD/scid-IL-2Rγcnull Mouse Brain Atlas
....................................................................................................................................... 109

4.1. Introduction ......................................................................................................... 110

4.2. Materials and methods ....................................................................................... 112

4.2.1. Experimental animals ..................................................................................... 112

4.2.2. Human CD34+ HSC reconstitution (humanization) of NSG mice ............... 112

4.2.3. MnCl2 administration ...................................................................................... 113

4.2.4. MRI data acquisition ...................................................................................... 113

4.2.5. Population averaged MRI mouse brain .......................................................... 114

4.2.6. Structures delineation and labeling ................................................................. 115

4.3. Results ............................................................................................................. 115

4.3.1. Brain structures labeling ................................................................................. 115
4.4. Discussion ................................................................................................................. 122
4.5. Conclusion ............................................................................................................... 122
4.6. References ............................................................................................................. 124

CHAPTER - 5: Potential of N-acetylated-para-aminosalicylic Acid to Accelerate Manganese Enhancement Decline for Long-term MEMRI in Rodent Brain .......... 129

5.1. Introduction ............................................................................................................ 130
5.2. Materials and Methods ........................................................................................ 131
  5.2.1. Study Design ...................................................................................................... 131
  5.2.2. AcPAS Synthesis .............................................................................................. 132
  5.2.3. High performance liquid chromatography (HPLC) ........................................ 133
  5.2.4. MnCl₂ and AcPAS treatment ........................................................................... 134
  5.2.5. MRI ................................................................................................................... 134
  5.2.6. ICP/MS Analyses ............................................................................................ 136
  5.2.7. Statistical Analysis .......................................................................................... 136
5.3. Results .................................................................................................................. 137
  5.3.1. AcPAS plasma and brain levels ..................................................................... 137
  5.3.2. MRI ................................................................................................................... 137
  5.3.3. Mn²⁺ enhancement ....................................................................................... 137
5.4. Discussion ............................................................................................................. 139
5.5. References ........................................................................................................ 147

CHAPTER 6: Summary, Limitations, and Future Directions .......................... 153
LIST OF FIGURES

Figure 1.1. MRI units for rodents at UNMC bio-imaging core facility.......................... 18

Figure 1.2. MEMRI in experimental neuroscience....................................................... 19

Figure 1.3. Three-dimensional MRI image of mouse brain with and without Mn$^{2+}$ ...... 20

Figure 1.4. Scheme of Mn$^{2+}$ transport mechanism in CNS ........................................ 21

Figure 1.5. Temporal Mn$^{2+}$ distribution across the brain............................................. 22

Figure 1.6. MEMRI measures neuronal activity............................................................. 23

Figure 1.7. MEMRI detects neuronal tracts................................................................. 24

Figure 1.8. Measurement of $R_1$ values ...................................................................... 25

Figure 2.1. Schematic depiction of co-cultured PC-12 cells (differentiated to neurons) with primary astrocytes or microglia................................................................. 38

Figure 2.2. Mn$^{2+}$ concentration in PC-12 cells co-cultured with astrocytes and microglia .......................................................................................................................... 48

Figure 2.3. T$_1$-wt images and enhancement quantification............................................. 51

Figure 2.4. Immunohistology......................................................................................... 53

Figure 2.5. Correlation comparisons.............................................................................. 54

Figure 3.1. Timeline of study....................................................................................... 83

Figure 3.2. Comparison of MEMRI enhancement between HIV-1 infected animals and controls.................................................................................................................. 88

Figure 3.3. Immunohistology of the hippocampus sub-regions including CA1, CA3 and DG ............................................................................................................................... 92

Figure 3.4. Association of immunohistology with MEMRI ............................................ 93

Figure 3.5. cFos expression at hippocampus region...................................................... 94
Figure 3.6. The mechanism of MEMRI in the detection of neuropathology in HIV-1 infected humanized mice .......................................................... 96

Figure 4.1. Three-dimensional presentation of mouse brain atlas .................. 118

Figure 5.1. Study design ............................................................................... 142

Figure 5.2. AcPAS concentrations measured by HPLC in plasma and in the brain regions .................................................................................. 143

Figure 5.3. Manganese enhancement maps ................................................ 144

Figure 5.4. Brain regions with significant signal intensity decrease ............... 145
LIST OF TABLES

Table 1.1. LD$_{50}$ (toxicity) data for MnCl$_2$ ................................................................. 26

Table 3.1. Brain regions that showed significant signal enhancement .................. 90

Table 3.2. Brain regions that showed trend of signal enhancement increase............. 91

Table 4.1. List of brain regions labeled on MEMRI brain atlas............................... 119

Table 5.1. Brain regions with significantly decreased enhancement in mice after 1 and 2 weeks high dose AcPAS treatment compared to in PBS controls ....................... 146
ACKNOWLEDGEMENTS

I like to start my acknowledgements by saying that I had best 5 years of my life during my Ph.D. training at UNMC, Omaha. I will treasure every moment I spent here and it was possible because of each and every person I came to know during last 5 years. It is hard to acknowledge every person in couple of pages and also, I am wordless to express my sincere gratitude towards them. Therefore, I like to thank god for bringing these people in my life.

First of all, I like to express my sincere and utmost gratitude to my parents (Navnath and Chandraprabha Bade), my brother and sister-in-law (Mahesh and Asha Bade), my nephew (Vedant), and my all family members for their support, encouragement and endless love. They have been great inspiration throughout my life. Without them, I wouldn’t be who I am today.

Next to my parents, I would like to express my gratitude to my advisor Dr. Yutong Liu. I would like to thank him for giving me the opportunity to work in his laboratory. He always considered and valued my opinion, encouraging me to think and bring new research ideas to discuss with him. He was always available and easy to approach whenever I needed his help or advice. Being from non-radiology background, I needed lot of help and time to learn things related to MRI, but Dr. Liu was very patient, supportive and encourager during those times. Dr. Liu’s qualities such as hard work, positive attitude, generosity and always smile on his face, influenced me most as a scientist. Dr. Liu has been a well-rounded advisor. I always received the best advice from him not only for research, but also for personal life and career. I am very thankful to
his support, encouragement, patience, availability, guidance, and appreciation throughout my training.

I am sincerely thankful to Dr. Howard E. Gendelman, who introduced me to Dr. Liu. Dr. Howard E. Gendelman played instrumental and significant role in influencing my research career. He has been a huge inspiration not only in my but also in many students personal as well as professional life. I feel very fortunate that I had opportunity to work in his laboratory. I am very thankful to his support, encouragement, availability, guidance and extensive training.

I would like extend my gratitude to the members of my advisory committee, which includes Dr. Michael D. Boska, Dr. Santhi Gorantla, Dr. Larisa Y. Poluektova and Dr. Shilpa Buch, for their valuable inputs, suggestion and constructive criticism during my graduate training. I especially like to thank Dr. Boska, Dr. Gorantla and Dr. Poluektova for their help, encouragement, support and guidance. I am also greatly appreciative to Dr. Gorantla for her support, encouragement, advice and lively valuable discussions about my research and career.

I would also like to thank my lab mates, who made me feel like home, helped me to learn different techniques, science, social behavior and many more things, and became my good friends. I shared many pleasant moments with these guys. For those reasons, I like to express my gratitude to current and previous lab members, including Dr. Prasanta Dash, Edward Makarov, Jaclyn Hollinger, Weizhe Li, Dr. Raghubendra Dagur, Dr. Divya Prakash Gnanadhas, Hang Su, Amanda Branch, Yan Cheng, Dr. Adrian Epstein, Dr. Tanuja Gutti, Dr. Zhang Gang, Sidra Akhter, Natasha Fields, Marnee Roundtree, Dr. Shantanu Balkundi, Dr. Pavan Puligijja, James Hilaire, and Brady Sillman.
I would like to thank bioimaging core facility and all the members associated with it, including Dr. Balasrinivasa R. Sajja, Dr. Mariano Uberti, Melissa Mellon, Ahmad Tanwir, Chris Woldstad, Dr. Dong J, Lirong Xu, and previous members, Biyun Zhou, Bruce Berrigan, for their the help, support, and friendship. I like to thank Dr. Uberti for his help with imaging softwares. I also like to extend my gratitude to Dr. Sajja for his valuable advice for research, lively discussions about career and all the coffees he bought for me during those discussions.

Many thanks to our department administrative staff, Leticia Tran, Theresa Grutel, Lana Reichardt, Robin Taylor, Kim Morrison, Julie Ditter, Johna Belling, Sandy Mahoney, Myhanh Che, Na Ly, and Reed Felderman for their enormous administrative help and support throughout my Ph.D. I would also like to thank to member of bioimaging core facility, Marie Witthoft, for her administrative help and support.

It will be incomplete without thanking my friends, who were there in my good and bad times. Without them, it would be hard to get through the graduate training, especially when my family is thousands of miles away. I will cherish every moment that I spent with them. I especially like to thank Dr. Swapnil Desale, Dr. Nilesh Wagh, Dr. Pavan Puligujja, Dr. Ariel Burns, Shrey Kanvinde, Prathamesh Patil, Vijay Yajjala, Vamsi Karuturi, and Shailendra Tallapaka. I also like to thank our daily lunch group, which made me laugh every day and forget about any stressful moment I had. I learned so many new things during our lunch conversations, not only about science but also about social/general life which helps me in day to day life. I had opportunity to serve in several student groups and committees, through these committees I was able to meet official people, make new friends and learn from their professional experience. I especially like
to thank UNMC Graduate Student Association and The International - Global Health Faculty and Student Advisory Committee.

Aditya N. Bade

December, 2015
Development of Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) Methods to Study Pathophysiology Underlying Neurodegenerative Diseases in Murine Models

Aditya N. Bade, Ph.D.

University of Nebraska Medical Center, 2015

Supervisor: Yutong Liu, Ph.D.

Manganese-enhanced magnetic resonance imaging (MEMRI) opens the great opportunity to study complex paradigms of central nervous system (CNS) in freely behaving animals and reveals new pathophysiological information that might be otherwise difficult to gain. Due to advantageous chemical and biological properties of manganese (Mn²⁺), MEMRI has been successfully applied in the studies of several neurological diseases using translational animal models to assess comprehensive information about neuronal activity, morphology, neuronal tracts, and rate of axonal transport. Although previous studies highlight the potential of MEMRI for brain imaging, the limitations concerning the use of Mn²⁺ in living animals and applications of MEMRI in neuroscience research are in their infancy. Therefore, development of MEMRI methods for experimental studies remains essential for diagnostic findings, development of therapeutic as well as pharmacological intervention strategies.

Our lab has been dedicating to develop novel MEMRI methods to study the pathophysiology underlying neurodegenerative diseases in murine models. In the first study, we investigated the cellular mechanism of MEMRI signal change during neuroinflammation in mice. The roles of neural cells (glia and neurons) in MEMRI signal enhancement were delineated, and ability of MEMRI to detect glial (astrocyte and
microglia) and neuronal activation was demonstrated in mice treated with inflammatory inducing agents. *In vitro* work demonstrated that cytokine-induced glial activation facilitates neuronal uptake of Mn$^{2+}$, and that glial Mn$^{2+}$ content was not associated with glial activation. The *in vivo* work confirmed that MEMRI signal enhancement in the CNS is induced by astrocytic activation by stimulating neuronal Mn$^{2+}$ uptake. In conclusion, our results supported the notion that MEMRI reflects neuronal excitotoxicity and impairment that can occur through a range of insults that include neuroinflammation.

In the second study, we evaluated the efficacy of MEMRI in diagnosing the complexities of neuropathology in an animal model of a neurodegenerative disease, neuroAIDS. This study demonstrated that MEMRI reflects brain region specific HIV-1-induced neuropathology in virus-infected NOD/scid-IL-2Rγc$^{null}$ humanized mice. Altered MEMRI signal intensity was observed in affected brain regions. These included, but were not limited to, the hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, substantia nigra and cerebellum. MEMRI signal was coordinated with levels of HIV-1 infection, neuroinflammation (astro- and micro- gliosis), and neuronal injury.

Following the application of MEMRI to assess HIV-1 induced neuropathology in immune deficient mice humanized with lymphoid progenitor cells, our successful collaboration with Dr. Sajja BR (Department of Radiology, UNMC, Omaha, NE) led to the generation of a MEMRI-based NOD/scid-IL-2Rγc$^{null}$ (NSG) mouse brain atlas. Mouse brain MRI atlases allow longitudinal quantitative analyses of neuroanatomical volumes and imaging metrics. As NSG mice allow human cell transplantation to study human disease, these animals are used to assess brain morphology. MEMRI provided sufficient contrast permitting 41 brain structures to be manually labeled on average brain of 19
mice using alignment algorithm. The developed atlas is now made available to researchers through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website (https://www.nitrc.org/projects/memribrainatlas/).

Finally, we evaluated the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate Mn$^{2+}$ elimination from rodent brain, enabling repeated use of MEMRI to follow the CNS longitudinally in weeks or months as well as inhibiting the confounding effects of residual Mn$^{2+}$ from preceding administrations on imaging results. Two-week treatment with AcPAS (200 mg/kg/dose × 3 daily) accelerated the decline of Mn$^{2+}$ induced enhancement in MRI. This study demonstrated that AcPAS could enhance MEMRI utility in evaluating brain biology in small animals.
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MEMRI</td>
<td>Manganese-enhanced magnetic resonance imaging</td>
</tr>
<tr>
<td>Mn$^{2+}$</td>
<td>Manganese</td>
</tr>
<tr>
<td>Ca$^{2+}$</td>
<td>Calcium</td>
</tr>
<tr>
<td>Gd</td>
<td>Gadolinium</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>MOBgl</td>
<td>Main olfactory bulb, glomerular layer</td>
</tr>
<tr>
<td>MOBgr</td>
<td>Main olfactory bulb, granule layer</td>
</tr>
<tr>
<td>AOB</td>
<td>Accessory olfactory bulb</td>
</tr>
<tr>
<td>AON</td>
<td>Anterior olfactory nucleus</td>
</tr>
<tr>
<td>PIR</td>
<td>Piriform area</td>
</tr>
<tr>
<td>DG-mo</td>
<td>Dentate gyrus_molecular layer</td>
</tr>
<tr>
<td>DG-(po+sg)</td>
<td>Dentate gyrus_(polymorph layer + granular layer)</td>
</tr>
<tr>
<td>CP</td>
<td>Caudoputamen</td>
</tr>
<tr>
<td>LSX</td>
<td>Lateral septal complex</td>
</tr>
<tr>
<td>STRv</td>
<td>Striatum ventral region</td>
</tr>
<tr>
<td>PALc</td>
<td>Pallidium, caudal region</td>
</tr>
<tr>
<td>GP</td>
<td>Globus pallidus</td>
</tr>
<tr>
<td>MS</td>
<td>Medial septal nucleus</td>
</tr>
<tr>
<td>AMY</td>
<td>Amygdala</td>
</tr>
<tr>
<td>cc</td>
<td>Corpus callosum</td>
</tr>
<tr>
<td>opt</td>
<td>Optic tract</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>ac</td>
<td>Anterior commissure</td>
</tr>
<tr>
<td>RFB</td>
<td>Rest of fiber tracts</td>
</tr>
<tr>
<td>TH</td>
<td>Thalamus</td>
</tr>
<tr>
<td>EPI</td>
<td>Epithalamus</td>
</tr>
<tr>
<td>HY</td>
<td>Hypothalamus</td>
</tr>
<tr>
<td>IC</td>
<td>Inferior colliculus</td>
</tr>
<tr>
<td>PAG</td>
<td>Periaqueductal gray</td>
</tr>
<tr>
<td>PRT</td>
<td>Pretectal region</td>
</tr>
<tr>
<td>SN</td>
<td>Substantia nigra</td>
</tr>
<tr>
<td>RMB</td>
<td>Rest of midbrain</td>
</tr>
<tr>
<td>P</td>
<td>Pons</td>
</tr>
<tr>
<td>MY</td>
<td>Medulla</td>
</tr>
<tr>
<td>CBXmo</td>
<td>Cerebellar cortex, molecular layer</td>
</tr>
<tr>
<td>CBXgr</td>
<td>Cerebellar cortex, granular layer</td>
</tr>
<tr>
<td>CBwm</td>
<td>Cerebellar white matter</td>
</tr>
<tr>
<td>FN</td>
<td>Fastigial nucleus</td>
</tr>
<tr>
<td>IP</td>
<td>Interpose nucleus</td>
</tr>
<tr>
<td>DN</td>
<td>Dentate nucleus</td>
</tr>
<tr>
<td>VL</td>
<td>Lateral ventricles</td>
</tr>
<tr>
<td>V3</td>
<td>Third ventricle</td>
</tr>
<tr>
<td>AQ</td>
<td>Cerebral aqueduct</td>
</tr>
<tr>
<td>V4</td>
<td>Fourth ventricle</td>
</tr>
<tr>
<td>HIP</td>
<td>Hippocampus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>NITRC</td>
<td>Neuroimaging Informatics Tools and Resources Clearinghouse</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>Dox</td>
<td>Doxycycline</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor necrosis factor alpha</td>
</tr>
<tr>
<td>ICP/MS</td>
<td>Inductively coupled plasma mass spectrometry</td>
</tr>
<tr>
<td>GFAP</td>
<td>Glial fibrillary acidic protein</td>
</tr>
<tr>
<td>Iba-1</td>
<td>Ionized calcium binding adaptor molecule 1</td>
</tr>
<tr>
<td>DAB</td>
<td>3,3’-diaminobenzidine</td>
</tr>
<tr>
<td>SYN</td>
<td>Synaptophysin</td>
</tr>
<tr>
<td>MAP2</td>
<td>Microtubule-associated protein 2</td>
</tr>
<tr>
<td>NF</td>
<td>Neurofilament</td>
</tr>
<tr>
<td>DAPI</td>
<td>4,6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>HAND</td>
<td>HIV-1-associated neurocognitive disorders</td>
</tr>
<tr>
<td>ANI</td>
<td>Asymptomatic neurocognitive impairment</td>
</tr>
<tr>
<td>MND</td>
<td>Mild neurocognitive disorder</td>
</tr>
<tr>
<td>HAD</td>
<td>HIV-associated dementia</td>
</tr>
<tr>
<td>1H MRS</td>
<td>Proton magnetic resonance spectroscopy</td>
</tr>
<tr>
<td>DTI</td>
<td>Diffusion tensor imaging</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence-activated cell sorting</td>
</tr>
<tr>
<td>VL</td>
<td>Viral load</td>
</tr>
<tr>
<td>T₁-wt</td>
<td>T₁-weighted</td>
</tr>
</tbody>
</table>
AcPAS  N-acetylated-para-aminosalicylic acid
PAS  Para-aminosalicylic acid
HPLC  High-performance liquid chromatography
CHAPTER – 1

Manganese (Mn$^{2+}$) -Enhanced Magnetic Resonance Imaging

(MEMRI)
1.1. Introduction

As being an excellent non-invasive tool with high spatial resolution and outstanding capacity for differentiating soft tissues to provide anatomical information of biological systems, magnetic resonance imaging (MRI) has become a pillar of radiological techniques in diagnostic imaging and has emerged as the major mode for assessing central nervous system (CNS) disorders [1]. MRI was introduced three decades ago into the clinical medicine [1]. Due to its properties, a variety of controls over image contrast, great flexibility and specificity in the detection of different pathophysiological mechanisms, metabolism assessment and anatomical as well as functional mapping, MRI has achieved widespread success not only in clinical, but also in research field [1-3]. Over the last 10 years, MRI utilization in experimental science has augmented [2][4,5]. Specially designed MRI units for experimental animals are now commercially available. Pictures of MRI units available for rodents at University of Nebraska Medical Center (UNMC) bio-imaging core facility are shown in figure 1.1. MRI acquisition softwares as well as post-processing tools are widely accessible [2]. Public and private financial sources have reinforced the expansion of MRI based brain atlases and databases [2].

In neuroscience research, innovations in diagnostic and therapeutic fields employing experimental animals rely on MRI. Availability of MRI in clinical as well as preclinical settings permits direct linking of findings between humans and experimental animals [3]. This non-invasive imaging tool has been used in the studies involving animal models of several neurological diseases, such as stroke, Parkinson’s disease, Alzheimer’s disease, and NeuroAIDS, epilepsy, brain tumors, multiple sclerosis, and other brain disorders [1-3,6-8].
Advances in MRI applications provide remarkable information about brain morphology, metabolism, physiology and function. The desire of obtaining more detailed information from brain, during normal and diseased conditions, with the help of MRI to improve our understanding is becoming more prominent. Thus, the interest in the use of contrast agents is increasing.

1.2. MRI contrast agents [1,9-13]

MRI uses hydrogen atoms of water molecules to generate images. The primary contrast in MRI image mainly results from regional differences in intrinsic factors, $T_1$ and $T_2$, spin-lattice and spin-spin, relaxation times. Proton density (PD), which is also termed as spin density (SD) is another factor affecting image contrast. These factors are independently chosen to generate the tissue image contrast. The differentiation between healthy and diseased tissue depends upon their distinctive signal intensity that relies on tissue PD, $T_1$ and $T_2$ relaxation times. However, the signal intensity generated by these intrinsic contrast factors of healthy and diseased tissue frequently too limited to enable sensitive and specific diagnosis. Intrinsic relaxation times of healthy and diseased tissues frequently overlap, leading to compromised detection of abnormal tissue or function. This limitation can be overcome by using MRI contrast agents.

Agents that affect the MRI signal contrast are paramagnetic (e.g. $\text{Mn}^{2+}$, Gd), and superparamagnetic (e.g. iron oxide particles, such as $\text{Fe}_2\text{O}_3$, $\text{Fe}_3\text{O}_4$) and ferromagnetic (e.g. albumin coated magnetite). These agents help to increase sensitivity and specificity of MRI signal acquisition and provide substantial diagnostic information by reducing $T_1$ and $T_2$ relaxation times of surrounding water protons in targeted tissue, leading to
generation of signal enhancement in shorter period of time and better signal-to-noise ratio.

In biomedical research, most widely used contrast agents are paramagnetic and superparamagnetic. Depending upon the characteristics, such as chemical composition, molecular size, \textit{in vivo} distribution, pharmacokinetic properties, and individual’s research question, agents are chosen for different studies. In our lab, we have used paramagnetic agent, Mn$^{2+}$, to study neurodegenerative diseases that are modeled using rodents, due to its advantageous chemical and biological properties.

1.3. Paramagnetic contrast agents

Lauterbur \textit{et al.} first suggested the use of paramagnetic ions as contrast agent for MRI in 1978 [14]. Paramagnetic agents possess a permanent magnetic moment, which are randomly aligned in the absence of an externally applied magnetic field. When paramagnetic material senses externally applied magnetic field, the respective magnetic moments align parallel to the applied field. Furthermore, aligned magnetic moments generate a local magnetic field, leading to an effective reduction in $T_1$ (spin-lattice) and $T_2$ (spin-spin) relaxation times of surrounding water protons of the targeted organ systems. Reduction in the relaxation times results in MRI signal changes [1,9,10,12].

Paramagnetic property of the material is based on the presence of number of unpaired electrons in atom. Most known subgroups of paramagnetic compounds are metal ions (e.g. Mn$^{2+}$) and lanthanide elements (e.g. gadolinium (Gd)). The magnetic moment of unpaired electrons is greater than that of unpaired neutrons or protons. Therefore, agents with unpaired electrons are exclusively apt as MRI contrast agent
Even though, paramagnetic agents affect both $T_1$ and $T_2$ relaxation times, the shortening of $T_1$ mainly causes an increase in signal intensity. The result of increase in signal intensity remains until the concentration of agent is reached to optimal level. Thus, use of paramagnetic material as a MRI contrast agent is advantageous, as it exhibits greater effects on $T_1$ than on $T_2$ relaxation time.

1.4. Mn$^{2+}$ – a paramagnetic contrast agent

Mn$^{2+}$, divalent ion, has paramagnetic properties. It has 5 unpaired electrons and causes strong reduction of both $T_1$ and $T_2$ relaxation times of surrounding water protons of targeted tissue [6,13,15,16]. The magnitude of $T_1$ or $T_2$ relaxation time reduction depends on the local Mn$^{2+}$ concentration. It can be described by following equation [13]:

$$R_{i_o} = R_t(0) + R_i [Mn^{2+}]$$

Where,

- $R_{i_o} = 1/T_i$ (i=1,2) is the observed relaxation rate
- $[Mn^{2+}]$ = the concentration of the Mn$^{2+}$ ion
- $R_i$ = the relaxivity constant, and
- $R_t(0) = the$ relaxation rate of the solvent without manganese ([Mn$^{2+}$] = 0)

The use of Mn$^{2+}$, a divalent ion, and its unique properties as a MRI contrast agent is known as Mn$^{2+}$-enhanced magnetic resonance imaging (MEMRI).

1.5. MEMRI

The investigation of Mn$^{2+}$ as contrast agent coincides with early days of nuclear magnetic resonance (NMR) [4,6,17]. Initial findings with the help of Mn$^{2+}$ played important role in
understanding of water-exchange effects, which was a crucial step in the development of 
$T_1$ shortening contrast agents [4,6,18,19], and quantitative structural information of 
biological systems, which helped to develop techniques to confirm three-dimensional 
protein structure using NMR [4,20]. Mn$^{2+}$ has been present since the beginning of MRI. 
Lauterbur et al. with the help of Mn$^{2+}$ showed that relaxation times could affect signal 
intensity. Over 25 years ago, the use of Mn$^{2+}$ as a MRI contrast agent was initialized. 
London et al. studied toxic effects of Mn$^{2+}$ on anesthetized rats [21]. Since then, the use 
of MEMRI in experimental neuroscience for imaging the rodent brain has significantly 
evolved [4]. Our observation about MEMRI use in neuroscience research over the last 10 
years is showed in figure 1.2.a and 1.2.b. Paramagnetic property of Mn$^{2+}$ causes an 
effective reduction of the $T_1$ (spin-lattice) relaxation times of the surrounding water 
protons of the targeted organs, leading to signal enhancement. Positive contrast signal 
enhancement is detected on $T_1$-weighted images of tissues in which Mn$^{2+}$ accumulates 
[4,6,9,12,15,16,22]. The difference between 3-D MRI image of brain of a mouse which 
was injected with MnCl$_2$ and 3-D MRI image of a brain of a mouse injected with saline 
showed in figure 1.3. Mn$^{2+}$-based contrast enhancement and neuroarchitecture details are 
clearly visible in these mice. Yet, one major weakness of Mn$^{2+}$ is associated cellular 
toxicity upon overexposure [4-6,12,15,16,23]. However, Mn$^{2+}$ is considered as least toxic 
among the essential trace elements. This divalent ion is also an essential trace element, as 
the lack of it leads to severe disorders in humans [5,6,16,24].

Interpretation of MEMRI findings requires profound knowledge of Mn$^{2+}$ behavior 
in biological systems under healthy and diseased conditions as well as of experimental 
considerations. Therefore, following sections will introduce the properties of Mn$^{2+}$ and its
entrance in the CNS, main applications of MEMRI in biological systems, methodological considerations of Mn\textsuperscript{2+} administration in animals, Mn\textsuperscript{2+} toxicity, MEMRI in humans, and objective and related study aims of my Ph.D. thesis.

1.6. Properties of Mn\textsuperscript{2+} in the CNS

Mn\textsuperscript{2+} is recognized by biological systems as a chemical analogue of calcium (Ca\textsuperscript{2+}), same charge and similar ionic radii (Mn\textsuperscript{2+} = 89 pm and Ca\textsuperscript{2+} = 114 pm) [6]. Therefore, Mn\textsuperscript{2+} can enter into the neurons and other excitable cells through voltage-gated calcium channels (L-type voltage-gated Ca\textsuperscript{2+} channels), NMDA receptors, Na\textsuperscript{2+}/Ca\textsuperscript{2+} exchanger, and Na\textsuperscript{2+}/Mg\textsuperscript{2+} antiporter [4-6,12,15,25-30]. Once inside the cells, it binds with high affinity to proteins and nucleic acids. Inside the neuronal cells, Mn\textsuperscript{2+} accumulates in the endoplasmic reticulum (ER), is packaged into the vesicles and is transported along the axons anterogradely [5,6,25,27,31]. Upon reaching the pre-synaptic membranes it is released at the synaptic cleft and taken up by the adjacent neurons [4-6,15,25,27]. Scheme of Mn\textsuperscript{2+} transport mechanism between neurons in CNS is depicted in figure 1.4.

Systemic administration of Mn\textsuperscript{2+} leads to its accumulation in all tissues, significantly detected in liver, kidney, heart and brain [6,16,32,33]. As major route of entry for Mn\textsuperscript{2+} into the CNS is through CSF-Blood barrier, the time course, uptake and distribution of Mn\textsuperscript{2+} varies across the brain regions [6,15,16]. Initial Mn\textsuperscript{2+} accumulation occurs in the brain regions near to ventricles and then gets distributed throughout the entire brain. Contrast enhancement in CNS reaches to its equilibrium 24 hours after MnCl\textsubscript{2} administration (Figure 1.5) [6,15,16,32,34,35]. It has been shown that Mn\textsuperscript{2+} has very slow clearance rate from the brain. It can take up to 300 days to clear from the brain.
tissue [16]. Mn$^{2+}$ has long half-life in the brain, 51–74 days in rodents [16,36] and more than 100 days [6,37] in monkeys, whereas short half-life in visceral organs like liver and heart, which might indicate that Mn$^{2+}$ is carrier-transported into the brain, but not out of it [6,16,36]. Efflux of Mn$^{2+}$ from brain is not well studied but is believed that the efflux mechanism is diffusion mediated [6,38].

1.7. Entry of Mn$^{2+}$ into the CNS

Mn$^{2+}$ enters into the brain via the following three major routes [4-6,12,15,16].

After systemic administration of MnCl$_2$, Mn$^{2+}$ enters the brain through two different routes as follows:

1) Through choroid plexus via CSF (major and rapid entry route)

2) Through BBB by diffusion or active transport processes (minor entry route)

At physiological plasma Mn$^{2+}$ concentration, it is mainly transported across the endothelial cells of brain capillaries, and after bolus systemic injection of Mn$^{2+}$ (at high concentration), the major route of entry is via choroid plexus.

Application of Mn$^{2+}$ via the olfactory system provides the easiest route for Mn$^{2+}$ entrance into the brain, as olfactory tract is not protected by the BBB or other barriers. It has been shown in rodents that upon exposure to air containing Mn$^{2+}$, it is able to enter into the olfactory bulb via the olfactory epithelium.

3) Through olfactory nerve via olfactory epithelium

1.8. Mn$^{2+}$ - an intracellular contrast agent
Two essential factors have been derived from the results obtained with the help of Mn$^{2+}$ [16,22].

1) Signal received after MnCl$_2$ administration comes from the intracellular Mn$^{2+}$, whereas another popular paramagnetic MRI contrast agent, chelated gadolinium, remains extracellular. Therefore, MEMRI has been useful to map signal intensities according to cellular density of the targeted tissue, and thus to visualize brain cytoarchitecture.

2) Rate of Mn$^{2+}$ uptake is useful to detect normal and affected tissue functions. Normal uptake defines the normal function of the tissue. Therefore, disruption of Mn$^{2+}$ uptake serves as a biomarker to detect the pathological conditions such as stroke, neuroAIDS, epilepsy, etc.

### 1.9. Applications of MEMRI in experimental neuroscience

Depending upon above mentioned properties of Mn$^{2+}$, literature has divided the applications of MEMRI as a research tool in three major groups [5,6,15,16,22]. But, here, I have divided the applications in four major groups.

1) Measurement of neuronal activity (functional assessment); this application of MEMRI is termed as activation-induced MEMRI (AIM-MRI) [29]; figure 1.6

2) Assessment of anatomical/morphological details [6]; figure 1.3

3) Assessment of neuronal tracts and assessment of axonal connectivities [6]; figure 1.7

4) Assessment of rate of axonal transport [5]
Taking advantage of these applications, researchers have been using MEMRI in neurosciences to address problems using translational models of brain diseases.

1.10. Methodological considerations for Mn\textsuperscript{2+} administration

1.10.1 Preparation of MnCl\textsubscript{2} solution:

The most common and easy way to deliver Mn\textsuperscript{2+} to the experimental animals is through the injection of MnCl\textsubscript{2} solution [6,15,16]. After administration, MnCl\textsubscript{2} dissociates into Mn\textsuperscript{2+} and Cl\textsuperscript{-}. The salt material (MnCl\textsubscript{2}) is commercially available in three different grades in major biochemical companies, for example:

1) MnCl\textsubscript{2}, powder form, anhydrous, purified (> 99%), molecular weight (M.W.)- 125.84 g/mol (Sigma-Aldrich, St Louis, MO)

2) MnCl\textsubscript{2}·4H\textsubscript{2}O, flake form, hydrous, highly purified (99.99%), M.W.- 197.91 g/mol (Sigma-Aldrich, St Louis, MO)

3) MnCl\textsubscript{2} solution, prepared in 18 megohm water, 1.00 ± 0.001 M (Sigma-Aldrich, St Louis, MO)

All three forms are suitable for experimental purpose. We have used MnCl\textsubscript{2}·4H\textsubscript{2}O for all the studies carried out in our laboratory and for studies mentioned in my dissertation.

Chemical and physical properties, especially osmolarity and pH, of the MnCl\textsubscript{2} solution to be used for experimental purpose need to be considered for successful application [6,15,16]. Osmolarity of body fluid is around 300 mOsm/l. One has to make sure that administered amount of MnCl\textsubscript{2} will not affect the natural osmolarity by using the isotonic solution of MnCl\textsubscript{2}, 100 mM. Solutions with significant lower osmolarity (<100 mM) are hypotonic, and solutions with significant higher osmolarity (>100 mM)
are hypertonic. This parameter has strong impact when MnCl$_2$ solution is injected directly into the brain tissue (stereotaxic injection), but has very minor consequences when injected systemically, including intravenous (IV), intraperitoneal (IP), subcutaneous (SC). For all of our studies, MnCl$_2$ has been administered systemically, especially through intraperitoneal route [25,39,40]. Therefore, we have been successfully using the MnCl$_2$ solution with lower concentration (50 mM).

Another important property to consider while preparing the MnCl$_2$ solution is pH. It is essential to adjust the pH of the solution at 7.4 for effective application. The procedure used to prepare MnCl$_2$ solution for our studies is described in materials and methods section of respective chapters.

### 1.10.2. Administration of Mn$^{2+}$

Due to acute and chronic cellular toxicity of Mn$^{2+}$, one has to take into consideration of experimental methodology, including delivery route, appropriate dose, osmolarity as well as pH of MnCl$_2$ solution to deliver adequate amount of Mn$^{2+}$ to the site of interest in a time efficient manner to receive desired contrast signal while avoiding any toxic effects of Mn$^{2+}$ to experimental animals and its interference with normal physiological properties.

It has been showed that systemic administration of MnCl$_2$ solution in a fractionated manner (i.e. smaller doses, multiple injections) is beneficial to reach sufficient Mn$^{2+}$ accumulation into tissues (especially brain) to obtain high contrast signal while minimizing toxic side effects [23,41]. We used fractionated administration scheme
for all of our studies [25,39,40]. Below, I have summarized commonly used administration routes for MnCl₂ solution in the literature.

In order to increase the efficiency of MEMRI, the delivery route is chosen based on the application [4,5,13,15,16]. MEMRI applications are described under the heading applications of MEMRI in experimental neuroscience in the current chapter. In general, MnCl₂ can be injected intraperitoneally (IP), intravenously (IV), subcutaneously (SC), intracranially (stereotaxic injection) into the area of interest, and can be delivered by using commercially available osmotic pumps. Among systemic administration routes (IP, SC, IV), there is no strong evidence suggesting that one route is better than others or that one route causes lesser toxicity compared to others.

Kuo et al. measured relative T₁ relaxation times in mice (C57Bl/6) brains with different modes of systemic administration (IP, IV, SC). Authors concluded that all the systemic routes of administration showed significant reduction in T₁ values following MnCl₂ infusion and both the temporal and regional changes in cerebral T₁ relaxation times are relatively independent of the route of administration [42].

Few studies have used osmotic pumps to deliver Mn²⁺ into the experimental animals [13,43,44]. Osmotic pumps deliver a specific concentration of Mn²⁺ over a specified period of time. It has been proposed that slow release of Mn²⁺ can decrease associated toxicity issues. Currently, ALZET® osmotic pumps company (Durect Corporation, CA) sales pumps in the market. Company describes that ALZET pumps operate on osmotic pressure difference between the tissue environment (in which the pump is implanted) and a compartment within the pump. When water enters into the pump compartment from the surrounding tissue, it compresses the flexible reservoir,
leading to displace MnCl$_2$ solution from the reservoir at a controlled rate to the surrounding body environment of the animal. ALZET provides a variety of delivery rates, SC or IP.

1.11. Mn$^{2+}$ - a trace element and related toxicity

Mn$^{2+}$ is an essential heavy metal for cellular processes and normal development. It plays essential role in the regulation of metabolism, cell energy, immune response, blood sugar homeostasis, blood clotting, reproduction, digestion, skeletal system development, bone growth as well as in synaptic function as an antioxidant and enzymatic cofactor in the brain [5,6,45,46]. It serves as a significant co-factor for enzymes such as glutamine synthetase, pyruvate carboxylase, arginase, phosphoenolpyruvate carboxykinase and mitochondrial superoxide dismutase [5,6,46,47]. In humans, deficiencies in Mn$^{2+}$ are associated with skin lesions, epileptic seizures, bone malformation, increased Ca$^{2+}$ and phosphorous levels, among others [5,16]. Mn$^{2+}$ is generally excreted through the hepatobiliary route [6,47,48]. However, in excess, Mn$^{2+}$ is toxic [4-6,15,16,47]. Acute overexposure to this ion happens when administered systemically to patients, leading to cardiac toxicity, renal failure, liver toxicity, and may be death [6,16]. Moreover, chronic exposure to Mn$^{2+}$ is neurotoxic, a brain disorder characterized by neurological and psychological disorders, a progressive neurodegenerative disorder, called as ‘Manganism’, accompanied by loss of Dopaminergic neurons [5,16]. In this disorder, Mn$^{2+}$ is highly concentrated in basal ganglia. Symptoms of manganism are similar to symptoms of Parkinson’s disease, such as tremors, widespread rigidity, hallucination, bradykinesia, sleep disorder, lack of facial expressions, slurred speech and memory loss.
It was observed that excessive exposure of this heavy metal damages the CNS by a number of mechanisms, including inhibition of mitochondrial oxidative phosphorylation, which leads to reduced ATP [49,50], impaired astrocyte-neuronal interactions, indirect effect on excitatory and inhibitory influences [47]. Aberrant Mn\(^{2+}\) accumulation in brain has also been linked to Huntington’s disease and other neurological disorders [49]. Normal human brain Mn\(^{2+}\) concentration is at 5.32-14.03 ng Mn\(^{2+}\)/mg protein, which is equivalent to 20-52.8 \(\mu\)M Mn\(^{2+}\) (around 1.1-2.9 ppm). General toxic responses occur when Mn\(^{2+}\) concentration is elevated to around 3 fold (i.e. 15.96-42.09 ng Mn\(^{2+}\)/mg protein or 60.1-158.4 \(\mu\)M Mn\(^{2+}\)) [49].

The most common method to administer Mn\(^{2+}\) to experimental animals is through the injection of MnCl\(_2\) solution. Detailed information about MnCl\(_2\) solution and administration routes are discussed under the heading preparation of MnCl\(_2\) solution and administration on Mn\(^{2+}\) in the current chapter. This paragraph discusses toxicity related to MnCl\(_2\). According to the Material Safety Data Sheet (MSDS) [16], MnCl\(_2\) is a harmful chemical agent, which causes eye and skin irritation upon contact. Target organs include the CNS and the lungs. As per the MSMDS report, following characteristic signs and symptoms of exposure have been identified: ‘Men exposed to manganese dusts showed a decrease in fertility. Chronic exposure primarily affects CNS, and early symptoms are languor, sleepiness and weakness in the legs.’ In more advanced cases, emotional disturbances such as uncontrollable laughter and a spastic gait with tendency to fall while walking. Mn\(^{2+}\) is also known to be a potential mutagen, and pneumonia is highly observed in the workers exposed to dust of Mn\(^{2+}\) compounds. Therefore, one must wear appropriate barriers and take proper precautions while interacting with MnCl\(_2\) material.
For experimental purposes. LD$_{50}$ toxicity data reports in the MSDS for MnCl$_2$ are shown in Table 1 [16].

Indeed, acute and chronic cellular toxicity of Mn$^{2+}$ repressed its transformation as clinical MRI contrast agent. Regardless of these toxicity issues, to take the advantage of chemical and biological properties of Mn$^{2+}$ as a contrast agent, researchers generated alternative ways to avoid toxicity of Mn$^{2+}$ while delivering sufficient amount of Mn$^{2+}$ to the site of interest in an efficient manner in experimental animals.

For all of our studies, level of Mn$^{2+}$ used is below the neurotoxic levels. Animals were observed daily after each i.p. MnCl$_2$ injection and 24 hours after the injection to detect Mn$^{2+}$ toxicity. If tremor or convulsion (signs of Mn$^{2+}$ overdose) persisted longer than 3 minutes or lethargy (decreased locomotion), and loss in body weight was observed at 24 hours, mice were euthanized [25]. Moreover, it is demonstrated that concentration of Mn$^{2+} > 200$ µM can affect the neuronal activity [51]. We measured the R$_1$ values to determine absolute Mn$^{2+}$ concentration before and after Mn$^{2+}$ administration in cortex region of mice (n=11). There was $\Delta 0.15$ alteration in R$_1$ values after Mn$^{2+}$ administration. R$_1$ values were less than 0.70 after Mn$^{2+}$ administration (Figure 1.8). These R$_1$ values then were compared with previously reported correlation between R$_1$ values and relative Mn$^{2+}$ concentration. This comparison corresponded to less than 40 µM Mn$^{2+}$ in the brain parenchyma region of experimental animal used in our studies (Figure 1.8). Thus, with the help of behavioral observation and measured R$_1$ values, we confirmed that our fractionated administration scheme for MnCl$_2$ is non-toxic to animals and injected Mn$^{2+}$ does not have effect on neuronal activity.
1.12. MEMRI in Humans

Even though the use of Mn$^{2+}$ as a MRI contrast agent in clinical settings has been restricted due to cellular toxicity, properties of Mn$^{2+}$ such as high sensitivity and specificity, and its prominent results in rodent, song birds, and monkeys, encouraged researchers to develop chelates of Mn$^{2+}$ for the clinical use. Several chelates were developed and few of them were introduced into the market by biochemical companies. Manganese dipyridoxalidiphosphate (MnDPDP) was the first Mn$^{2+}$-based contrast agent approved by FDA. This product was approved for the liver imaging [5,6,9,16,52,53]. Product containing Manganese dipyridoxalidiphosphate (MnDPDP) was introduced into the market by GE healthcare called Teslascan®. MnDPDP is anionic chelate and dissociates quickly after administration to yield free Mn$^{2+}$ ions. Although MnDPDP was mainly considered for liver imaging, some studies demonstrated its usefulness in imaging of pancreas and biliary tract [9]. Another pharma-company, Eagle Vision Pharmaceutical, is testing contrast agent called SeeMore® for cardiac imaging [5]. This product consists free Mn$^{2+}$ ions formulated along with Ca$^{2+}$ ions to outweigh the transient effect of Mn$^{2+}$ as a Ca$^{2+}$ inhibitor. This agent is currently used in dogs and pigs for cardiac and vascular imaging. Few promising chelating agents were invented for clinical use, however, further research needed for successful translation of MEMRI.

MEMRI has been successfully used in previous studies to study brain disorders in experimental animals. Although previous studies highlight the potential of MEMRI for brain imaging, the limitations and boundaries concerning the use of Mn$^{2+}$ in living animals and development of new MEMRI applications in neuroscience are at the beginning level. Therefore, during the course of my Ph.D, we have determined the
cellular source for altered signal intensity during pathological conditions, evaluated the
efficacy of chemical compound for washing out the Mn$^{2+}$ from the rodent brain for
longitudinal studies, and developed tools such as 3-D mouse brain atlas, which is now
available for public use at NIRTC resources.

1.13. Objective and aims of the thesis

1.13.1. Objective

To develop manganese-enhanced magnetic resonance imaging (MEMRI) methods to
study pathophysiology underlying neurodegenerative diseases in murine models.

1.13.2. Aims

1) Investigate role of glia and neurons in manganese-enhanced magnetic resonance
   imaging (MEMRI) signal enhancement during inflammation (Chapter 2).

2) Evaluate the application of MEMRI in diagnosing the brain pathology in animal
   models of neurodegenerative diseases (Chapter 3).

3) Generate MEMRI-based NOD/scid-IL-2R$\gamma$C$^\text{null}$ mouse brain atlas (Chapter 4).

4) Evaluate the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate
   Mn$^{2+}$ elimination from rodent brain (Chapter 5).
Figure 1.1. MRI units for small animals at UNMC bio-imaging core facility. Both scanners are 7 Tesla/21 cm, Bruker Biospin (Bruker, Billerica, MA)
Figure 1.2. MEMRI in experimental neuroscience. Distribution of MEMRI publications in (a) years and (b) neuroscience-related topics.
Figure 1.3. Three-dimensional MRI image of mouse brain with and without Mn$^{2+}$. 
Figure 1.4. Scheme of Mn$^{2+}$ transport mechanism in CNS. (a) Once Mn$^{2+}$ entered the CNS, it enters the neurons through voltage gated Ca$^{2+}$ channels. (b) Inside neurons, ions are accumulated in the endoplasmic reticulum and packaged into vesicles. (c) Mn$^{2+}$ ions are further transported anterogradely along the axons with the help of microtubule assembly. (d and e) Upon reaching to the presynaptic terminal, Mn$^{2+}$ ions get released at the synaptic cleft (f) and taken up by the adjacent neuron. Figure is modified from [12]
Figure 1.5. Temporal Mn$^{2+}$ distribution across the brain. (Top) Coronal, (middle) sagittal and (bottom) axial MEMRI sections of a mouse brain in vivo 2, 8, and 24 h after intraperitoneal injection of 320 μmol/kg MnCl$_2$ (9.4 T, 100 μm isotropic resolution). Cb, cerebellum; cp, choroid plexus; CSF, cerebrospinal fluid; dg, dental gyrus; fr, fasciculus retroflexus; gp, globus pallidus; ha, habenula; ic, inferior colliculus; ipn, interpeduncular nucleus; lh, lateral habenula; ls, lateral septum; ob, olfactory bulb; pi, pituitary gland; pv, periventricular tissue; str, striatum; th, thalamus. Figure is adapted from [6]
**Figure 1.6.** MEMRI measures neuronal activity. (a) MEMRI of acute cocaine-induced brain activation. Activation maps are superimposed onto T2-weighted MRI with corresponding rat brain atlas sections shown on the right. Activated voxels are clustered in the hemisphere with the BBB disrupted by hyperosmolar mannitol. The contralateral hemisphere had an intact BBB and did not show activation. Activated structures include olfactory cortex; medial, ventral, and lateral orbital cortex; pre-limbic cortex; cingulate cortex; nucleus accumbens (NAc), caudate putamen; ventral pallidus; external globus pallidus; agranular insular cortex; thalamus; hypothalamus; retrosplenial dysgranular cortex; hippocampus; and primary and secondary somatosensory and motor cortex. (b) Averaged MEMRI response time course in the NAc from animals receiving saline (n = 6) and 0.5 mg/kg (n = 5) and 2.0 mg/kg (n = 6) cocaine. All time courses were normalized to the baseline signal after bolus injection of mannitol, but before the injection of cocaine or saline. Figure is adapted from [29]
Figure 1.7. MEMRI detects neuronal tracts. (a, b) Horizontal and (c) axial MEMRI sections and (d) 3D volume rendering of a mouse optical system in vivo 24 h after intravitreal administration of 0.06 μmol MnCl2 (2.35 T, 117 μm isotropic resolution). lgn, lateral geniculate nucleus; och, optic chiasm; on, optic nerve; ot, optic tract; sc, superior colliculus. Figure is adapted from [6].
Figure 1.8. Measurement of R₁ values. (a) R₁ (1/T₁) values were measured in mice brain cortex before and after Mn²⁺ injections. Mice were injected with our lab optimized fractionated MnCl₂ injections. (n=11). (b) R₁ values plotted against MnCl₂ concentration, significant linear correlation was observed between the two (n = 4 MRI acquisitions, \( P < 0.0001, r: \) Pearson’s correlation coefficient). Panel b of the figure is adapted from [51]
Table 1.1. LD$_{50}$ (toxicity) data for MnCl$_2$.

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>250 mg/kg</td>
<td>Behavioral: somnolence (general depressed activity)</td>
</tr>
<tr>
<td></td>
<td>Intraperitoneal</td>
<td>147 mg/kg</td>
<td>Behavioral: convulsions or effect on seizure threshold</td>
</tr>
<tr>
<td></td>
<td>Intravenous</td>
<td>92.6 mg/kg</td>
<td>Behavioral: somnolence (general depressed activity)</td>
</tr>
<tr>
<td></td>
<td>Intramuscular</td>
<td>700 mg/kg</td>
<td>Behavioral: convulsions or effect on seizure threshold</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>1031 mg/kg</td>
<td>Behavioral: tremor</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>121 mg/kg</td>
<td>Behavioral: somnolence (general depressed activity)</td>
</tr>
<tr>
<td></td>
<td>Intravenous</td>
<td>38 mg/kg</td>
<td>Behavioral: ataxia</td>
</tr>
<tr>
<td></td>
<td>Intramuscular</td>
<td>255 mg/kg</td>
<td>Lungs, thorax or respiration: other changes</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>202 mg/kg</td>
<td>Lungs, thorax or respiration: other changes</td>
</tr>
<tr>
<td>Dog</td>
<td>Intravenous</td>
<td>916 mg/kg</td>
<td>Behavioral: tremor</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Intravenous</td>
<td>916 mg/kg</td>
<td>Behavioral: convulsions or effect on seizure threshold</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>916 mg/kg</td>
<td>Lungs, thorax or respiration: other changes</td>
</tr>
</tbody>
</table>

Source: MSDS for MnCl$_2$, (product number 244589, Sigma-Aldrich, St Louis, MO, USA).
1.14. References


CHAPTER - 2

Role of Glia and Neurons in Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) Signal Enhancement During Inflammation
2.1. Introduction

Manganese (Mn\(^{2+}\)) is a potent magnetic resonance imaging (MRI) contrast agent used to improve anatomical visibility, most notably, neural structures. Unlike other agents, such as gadolinium, iron oxide, iron platinum and protein-based compounds, Mn\(^{2+}\) remains at a very early stage in clinical development, based in large measure to its inherent neurotoxicity [1-3]. Nonetheless, a number of recent reports demonstrate that Mn\(^{2+}\)-enhanced MRI (MEMRI) in normal animal brains provide novel information relevant to anatomical, integrative, and functional assessments of neuronal connectivity. These findings are linked to the abilities of Mn\(^{2+}\) ions to efficiently enter neurons through voltage-gated calcium channels [4-7].

A major drawback for the use of Mn\(^{2+}\) as a contrast agent in studies of human disease models rests in understanding its cellular mechanism and profiles [8,9]. Despite such potential limitations, significant attempts have been made, in recent years, to use MEMRI in studies of the pathobiology of neurodegenerative diseases utilizing relevant animal models [9-25]. Nonetheless and paramount to the successful application of MEMRI is not simply the ability to deliver Mn\(^{2+}\) to the site of interest or of disease but in determining the cell types and cellular mechanisms that engage the ion and produce the signal enhancement observed. Based on our long standing interest in the links between neuroimmunity and neurodegenerative diseases we reasoned that pathological activation of the immune-competent glial cells could represent an obligatory event for any MEMRI signal enhancements. In support of this idea is a wealth of prior studies demonstrating that MEMRI signal enhancements were co-localized with reactive glia [14,22,26,27].

However, it was never clear if such signal enhancements resulted from Mn$^{2+}$ accumulation in the glial cells directly, or from elevated manganese uptake by neuronal cells stimulated by glial reaction.

Thus, we sought to better elucidate the cellular basis of MEMRI signal in studies of neurodegenerative diseases. We reasoned that if the cell association of the signal enhancement is determined, MEMRI can be developed as a potential imaging tool to monitor real-time glial-neuronal interactions. To this end, we investigated relationships between microglial and astrocytic activation linked to Mn$^{2+}$ uptake. These studies were both in vitro as performed in glial and neuronal cells and in vivo using MRI following lipopolysaccharide (LPS) treatments in mice. The results showed that astrocytic reactions result in MEMRI signal enhancement by stimulating neuronal Mn$^{2+}$ ion uptake.

### 2.2. Materials and Methods

#### 2.2.1. PC-12 Differentiation

A rat adrenal pheochromocytoma-derived cell line - PC-12 Tet-Off, was used to study neuronal Mn$^{2+}$ uptake. PC-12 cells were utilized here because they serve as a relevant in vitro model system for primary neuronal cells [28,29]. They have been widely used to study voltage-gated Ca$^{2+}$ channels [30,31] and effects of Mn$^{2+}$ exposure on these cells [2,32,33]. Following withdrawal of doxycycline (Dox) from the medium, PC-12 cells were differentiated with nerve growth factor (NGF, R&D Systems 1156-NG/CF).
2.2.3. Cell Co-culture and Activation

Figure 2.1. PC-12 cells (differentiated to neurons) were co-cultured with primary astrocytes or microglia respectively at the cell ratio of 1:1 ($10^5$ cells).

Primary cultured mouse astrocytes and microglia were prepared from $NOD$-$scid$ $IL2R_{null}$ (NSG) newborn pups as described in [34,35]. Differentiated PC-12 cells were de-attached and seeded in multi-well plates. Primary astrocytes and microglia were placed on inserts and co-cultured with PC-12 cells respectively at the cell ratio of 1:1 ($10^5$ cells, Fig. 2.1). The co-cultured cells were then treated with a combination of cytokines including interferon gamma (IFN-$\gamma$) and tumor necrosis factor alpha (TNF-$\alpha$) at the following concentrations: 25 (IFN-$\gamma$) and 2.5 (TNF-$\alpha$), 50 and 5.0, or 100 and 10.0 ng/ml to induce glial activation. After nine hours of treatment, MnCl$_2$ solution was administered in the medium at concentrations of 80, 160 and 320 $\mu$M. An untreated cell group was used for control measurements. Cells were washed and resuspended at 2 and 15 hours after MnCl$_2$ treatment. Inductively coupled plasma mass spectrometry (ICP/MS) was used to measure the Mn$^{2+}$ concentration. Experiments were performed with triplicate samples.
2.2.4. Mouse Model of Acute Neuroinflammation

All animal procedures performed in this study were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee. LPS was intracranially (i.c.) injected to induce focal inflammation in male wild-type C57BL/6 mice (n = 13, 6-8 weeks old). Using a stereotactic injection device, 10 µg (LPS) in 2 µl PBS was administrated into the left hemispheric caudoputamen (coordinates from bregma: 3.0 mm lateral, 0.5 mm anterior, and −3.5 mm ventral). The LPS solution was delivered with a 27 g needle at the flow rate of 0.2 µl per minute. A sham-operated control group (n = 11) was injected with 2 µl PBS through the i.c. route with the same parameters as the LPS group.

2.2.5. MEMRI

MnCl$_2$ (50 mM) was administrated i.p. with the dose of 60 mg/kg consecutively four times at 24 hour intervals before MRI. Another group of mice (n = 10) with i.c. LPS injection was added to study the effect of LPS alone on MRI signal enhancement. This group was administrated with saline through the i.p. route with the volume of 6 ml/kg at the same times as the MnCl$_2$ injection. The LPS mice injected with MnCl$_2$ are designated as LPS + MnCl$_2$ hereafter, and the LPS mice injected with saline are designated as LPS + saline. The sham-operated mice with i.c. PBS injection are designated as PBS + MnCl$_2$. One day after LPS or PBS injection, six LPS + MnCl$_2$ mice, five LPS + saline mice and five PBS + MnCl$_2$ mice were scanned using MRI. The remaining mice were scanned seven days after LPS or PBS injection. After MRI, the mice were euthanized and brains were removed for histology.
MRI was performed 24 hours after the last MnCl\textsubscript{2} injection on a 7T/21 cm horizontal bore scanner (Bruker, Billerica, MA) operating ParaVision 5.1 with a volume coil for RF transmission and a 4-channel phased-array coil for signal reception. Mice were scanned using T\textsubscript{1} mapping (fast spin echo with variable TR from 0.4 s to 10 s, 12 slices, slice thickness = 0.5 mm, in-plane resolution = 0.1x0.1 mm\textsuperscript{2}) and T\textsubscript{1}-wt MRI (gradient recalled echo, TR = 20 ms, flip angle = 20°, 3D isotropic resolution = 0.1 x 0.1 x 0.1 mm\textsuperscript{3}).

To reduce the influence of the inhomogeneous signal reception by the surface coil, N3 field inhomogeneity correction [36] was first performed on each image using MIPAV (CIT, NIH). The brain was then manually aligned to the LONI atlas (LONI, UCLA) in Analyze (AnalyzeDirect, KS). The alignment is necessary for accurate quantification of signal enhancement due to manganese uptake.

MRI signal enhancement was measured on a slice-by-slice basis in the axial direction. On each slice, the injection site was first identified. The mean value and standard deviation (SD) of the signal intensity about the corresponding location of the needle hole on the contralateral hemisphere was measured (in a larger ROI), then the intensity threshold was defined as the mean value plus 2 SDs. This threshold was applied on the ipsilateral hemisphere as the lower boundary to identify enhanced area about the needle hole. The enhanced volume was the summation of the enhanced areas multiplied by the slice thickness. The total enhanced volume was then normalized to the needle depth. The signal enhancement ratio was calculated by dividing the mean signal intensity in the enhanced volume by mean intensity on the contralateral side.
2.2.6. Immunohistology

Mice were euthanized immediately after MRI. Brains were collected and fixed in 4% paraformaldehyde overnight and embedded in paraffin. The paraffin blocks were cut into 5 μm thick sections. These brain tissue sections were then labeled with rabbit polyclonal antibodies for glial fibrillary acidic protein (GFAP) (1:1000, Dako, Carpinteria, CA). Microglia were stained with rabbit polyclonal antibodies for ionized calcium binding adaptor molecule 1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA). The polymer-based HRP-conjugated anti-mouse and anti-rabbit Dako EnVision systems were used as secondary detection reagents and 3,3’-diaminobenzidine (DAB, Dako) used as a chromogen. All paraffin-embedded sections were counterstained with Mayer's hematoxylin. Images were captured with a 10x objective using Nuance EX multispectral imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) was used for quantification of GFAP and Iba-1 expression in the region of interest (in and around the injection line) as reflected by intensity/μm². Area-weighted average intensity was calculated for GFAP and Iba-1 expression by dividing the total signal intensity, for each partitioned area, by area (μm²).

For immunofluorescence labeling, brain sections about the injection line were treated with the paired combination of primary antibodies mouse anti-synaptophysin (SYN) (1:1000, EMD Millipore), and rabbit anti-microtubule-associated protein 2 (MAP2) (1:750, EMD Millipore). Primary antibodies were labeled with secondary anti-mouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and nuclei were labeled with DAPI (4,6-diamidino-2-
phenylindole). Slides were coverslipped with ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA). Then slides were stored at −20°C after drying for 24 hours at room temperature. Images were captured at wavelengths encompassing the emission spectra of the probes, with a 10X objective by Nuance EX multispectral imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) used for quantification. For SYN and MAP2 expression, area-weighted average fluorescence intensity was calculated in the region of interest (in and around the injection line) by dividing the total signal intensity, for each partitioned area, by area (µm²) as intensity/µm².

2.2.7. Statistical Analysis

T-test was used to compare the cell manganese concentrations in the in vitro study. Correlation between manganese uptake by PC-12/glial cells and cytokine level were performed using Pearson’s correlation coefficient calculation. In the in vivo MEMRI study, t-test was used to compare all the variables in between LPS and PBS injected groups, whereas Pearson’s correlation coefficient was used to test for correlations between signal enhancement and glial reactivity.

2.3. Results

2.3.1. Mn²⁺ Uptake by PC-12 Cells

The manganese concentration in PC-12 cells co-cultured with astrocytes and microglia was shown in Fig. 2.2.a and 2.2.b, respectively. Mn²⁺ concentration in PC-12 cells was plotted against cytokine level (IFN-γ/TNF-α, ng/ml) at 2 and 15 hours of MnCl₂
incubation time (left and right plots, respectively). In this figure, several properties of the baseline manganese uptake by PC-12 cells (when IFN-γ/TNF-α = 0/0) are manifest. First of all, the measurements at MnCl$_2$ concentration = 0 shown in Fig. 2.2 by dash-dot lines demonstrated that PC-12 cells endogenous manganese was low, suggesting the manganese in PC-12 must be taken from the extrinsic source – the MnCl$_2$ solution. Secondly, the manganese uptake by PC-12 cells depends on the availability of the extrinsic manganese (i.e., the concentration of MnCl$_2$ solution). It can be seen that the PC-12 manganese concentration is positively correlated with MnCl$_2$ concentration in all the plots in Fig. 2.2 (Pearson’s correlation, r ≥ 0.900, p < 0.05). The incubation time of MnCl$_2$ apparently plays a role in PC-12 manganese uptake as well. The manganese concentration in PC-12 cells at 15 hours was much higher than at 2 hours, evidenced by comparing the left and right columns in Fig. 2.2 (p < 0.05 at MnCl$_2$ = 160 and 320 µM). These observations were in agreement with previous findings [3].

The role of glial reaction on PC-12 manganese uptake involves a number of factors including the glial cell type, and the level and time of glial reaction. Fig. 2.2 illustrates that the change in PC-12 manganese uptake resulted from astrocytic activation. At short inflammatory cytokine treatment time (2 hours), PC-12 manganese uptake was almost linearly increased with cytokine levels at 160 µM (Pearson’s correlation, r = 0.990, p < 0.01) and 320 µM (Pearson’s correlation, r = 0.998, p < 0.01). Prolonged treatment (15 hours) seemed to suppress the manganese uptake by PC-12 cells with cytokine levels at 160 and 320 µM MnCl$_2$. However the negative correlation between the manganese concentration and cytokine level was not significant (p = 0.064 at 160 µM, p = 0.052 at 320 µM).
On the other hand, microglial reaction had no significant impact on PC-12 manganese uptake. At the high MnCl$_2$ concentration (320 µM) and short treatment time (2 hours), it showed the trend of negative impact (Pearson’s correlation, $r = -0.935$, $p = 0.065$). The PC-12 manganese uptake remained constant at all other MnCl$_2$ concentrations at both 2 and 15 hours.

It was interesting to see that at 15 hours Mn$^{2+}$ uptake by PC-12 cells co-cultured with astrocytes at baseline (IFN-$\gamma$/TNF-$\alpha = 0/0$) was twice the concentration of Mn$^{2+}$ as PC-12 cells co-cultured with microglia. This result could be due to increase in Mn$^{2+}$ efflux from astrocytes in response to high extracellular Mn$^{2+}$ [37], which could cause increase in extracellular Mn$^{2+}$ concentration, and thus lead to more Mn$^{2+}$ uptake by PC-12 cells.

**2.3.2. Manganese Uptake by Glial Cells**

No significant exogenous manganese uptake by glial cells was observed in this study at any extracellular MnCl$_2$ concentration, glial activation level, or times of exposure (data not shown). The ICP/MS measurements showed that the intrinsic manganese content in astrocytes and microglia was 50-70 ppb, which is about 30-50 times higher than that of PC-12 cells at baseline (measured at 0 µM MnCl$_2$). The intrinsic manganese concentrations of glial cells measured in this work are in agreement with previous studies [38,39]. The high intrinsic Mn$^{2+}$ concentration in glial cells indicates that Mn$^{2+}$ is an important element for the function of glial cells.

**2.3.3. MRI Signal Enhancement and Enhanced Volume Measurements**
At Day 1 after LPS/PBS injections, signal enhancement was found only in 2 mice in each group. Signal enhancement at Day 1 was negligible as compared to Day 7, and was not significantly different between the LPS + MnCl\textsubscript{2} and PBS + MnCl\textsubscript{2} groups (Data not shown). At Day 7 after LPS injection, T\textsubscript{1}-wt images of the LPS + MnCl\textsubscript{2} group showed strong signal enhancement around the injection line compared to both the surrounding tissue and the corresponding region in the contralateral hemisphere. The T\textsubscript{1}-wt image of a Day 7 LPS + MnCl\textsubscript{2} mouse was shown in Fig. 2.3.a in three orthogonal planes: coronal (upper left), sagittal (upper right) and axial (bottom left). The areas around the injection line were encased by red boxes and shown in magnified windows in Fig. 2.3.a. The signal enhancement in this area was robust. The T\textsubscript{1}-wt image of a PBS + MnCl\textsubscript{2} mouse was shown in Fig. 2.3.b. The PBS injected mice showed minimal enhancement compared to the LPS injected mice. The enhancement ratios calculated in the PBS + MnCl\textsubscript{2} and LPS + MnCl\textsubscript{2} groups are shown in Fig. 2.3.c. Statistical analysis showed significantly higher signal enhancement ratio in the LPS + MnCl\textsubscript{2} group as compared to the PBS + MnCl\textsubscript{2} group, \( p < 0.01 \). Similarly as shown in Fig. 2.3.d, enhanced tissue volumes (after normalization by injection depths) were significantly larger in the LPS + MnCl\textsubscript{2} group than in the PBS + MnCl\textsubscript{2} group, \( p < 0.001 \). There was no obvious signal enhancement in the mice injected with only LPS but not MnCl\textsubscript{2} (the LPS + saline group) as shown in Fig. 2.3.e.

**2.3.4. Immunohistology**

At Day 1 after LPS/PBS injection, no reactive astrocytes were found, and only microglia detected by Iba-1 were observed in LPS injected mice around the injection line. A brain
slice of a LPS + MnCl$_2$ mouse at Day 1 is shown in Fig. 2.4.a. The Iba-1 staining on a region around the injection line (red box) is shown in a magnified (20X) window. As described in the preceding paragraph, no significant MEMRI signal enhancement was observed in these mice (data not shown). Both astrocytic and microglial reactivity were detected at Day 7 in LPS injected mice. The top row in Fig. 2.4.b shows a brain slice of a LPS + MnCl$_2$ mouse at Day 7. The GFAP and Iba-1 staining on a region around the injection line are shown in magnified (20x) windows. It can be seen that a large number of activated astrocytes were detected by GFAP, and activated microglia by Iba-1, in this region. A brain slice of a PBS + MnCl$_2$ mouse is shown in the 2$^{nd}$ row in Fig. 2.4.b. The areas stained by GFAP and Iba-1 in the region about the injection line (red box) were much smaller compared to the LPS + MnCl$_2$ mouse. In quantitative analysis, at Day 7, the astrocytic reactivity represented by GFAP expression (p < 0.01) and microglial reactivity by Iba-1 expression (p < 0.05) were significantly higher in the LPS + MnCl$_2$ group than in the PBS + MnCl$_2$ group (Fig. 2.4.c). Immunofluorescence labeling for neuronal markers (SYN and MAP2) showed no significant difference in neuronal loss between LPS + MnCl$_2$ and PBS + MnCl$_2$ groups around the injection lines (data not shown).

Fig. 2.5.a shows that the correlation between astrocyte and microglial reactivity is significant (Pearson’s correlation coefficient, r = 0.62, p < 0.05) in the LPS + MnCl$_2$ group at Day 7. More interesting is that, at Day 7 in the LPS + MnCl$_2$ group, there was a significant correlation between astrocytic reactivity and enhanced tissue volume calculated from MEMRI data (Pearson’s correlation coefficient, r = 0.66, p < 0.05) as
shown in Fig. 2.5.b. No correlation was found between microglial reactivity and enhanced tissue volume.
Figure 2.2. Mn$^{2+}$ concentration in PC-12 cells co-cultured with astrocytes plotted against cytokine treatment level (IFN-γ/TNF-α, ng/ml) at 2 hours (Left) and 15 hours (Right) of MnCl$_2$ incubation. (b) Mn$^{2+}$ concentration in PC-12 cells co-cultured with microglia plotted against cytokine treatment level (IFN-γ/TNF-α, ng/ml) at 2 hours and 15 hours of MnCl$_2$ incubation.
Coronal, Sagittal, Axial

(d)

Enhancement Ratio (%)

PBS + MnCl₂  LPS + MnCl₂

**
Figure 2.3. T₁-wt images and enhancement quantification. (a) T₁-wt image of a PBS + MnCl₂ mouse. The image was shown in sagittal, coronal and axial directions (counter-clockwise starting from upper right). Areas around the injection line were encased by red boxes and shown in magnified windows. (b) T₁-wt image of a LPS + MnCl₂ mouse. (c) T₁-wt image of a LPS only (no MnCl₂ injection) mouse. No obvious signal enhancement was observed in the mice injected with only LPS but not MnCl₂. (d) Enhancement measurements. The LPS + MnCl₂ group showed significantly higher signal enhancement than the PBS + MnCl₂ group (p<0.01). (e) Enhanced volume. Enhanced volumes (normalized by dividing it by respective Injection depths). The LPS + MnCl₂ group showed significantly larger enhanced volumes (p<0.01).
(a) LPS + MnCl$_2$

(b) PBS + MnCl$_2$

(c) Graph showing intensity in GFAP and Iba-1 with treatments: PBS + MnCl$_2$ and LPS + MnCl$_2$.
Figure 2.4. Immunohistology. (a) A brain section of a LPS + MnCl$_2$ mouse at Day 1 after LPS injection. The reactive microglia by Iba-1 in the regions encased in red boxes about the injection line are shown at 20x. (b) A brain section of a LPS + MnCl$_2$ mouse (top row) and of a PBS + MnCl$_2$ mouse (2$^{nd}$ row). The reactive astrocytes by GFAP and microglia by Iba-1 in the regions encased in red boxes around the injection line are shown at 20x. (c) Glial reactivity quantification. Astrocytic and microglial reactivity represented by GFAP and Iba-1 expressions (Intensity/µm$^2$) were significantly higher in the LPS + MnCl$_2$ group compared to the PBS + MnCl$_2$ group (p < 0.01 and p < 0.05, respectively)
Figure 2.5. Correlation comparisons. (a) Correlation between astrocytic and microglial reactivity ($r = 0.62$, $p < 0.05$). (b) Correlation between astrocytic reactivity and enhanced volume ($r = 0.66$, $p < 0.05$)
2.4. Discussion

Intrinsic manganese content in neurons is low compared to glial cells, and neuronal manganese uptake is partly dependent on the availability of extrinsic manganese. Here we investigate the effect of glial reaction on glial and neuronal manganese uptake. The results suggest that inflammatory cytokine induced astrocytic activation [40] stimulates Mn$^{2+}$ uptake of neurons, and that this uptake is proportional to the level of activation. On the other hand, microglial reaction has no direct effect in stimulating neuronal Mn$^{2+}$ uptake, and intensive microglial reaction may even suppress uptake.

The intrinsic manganese content in astrocytes and microglia is much higher than in PC-12 cells as shown in this study and others [38,39]. The high intrinsic Mn$^{2+}$ concentration in glial cells indicates that Mn$^{2+}$ is an important element for the function of these cells. Studies have found that activity of several enzymes in the central nervous system is Mn$^{2+}$ dependent, such as superoxide dismutase, ATPase, and glutamine synthase [37]. No significant exogenous Mn$^{2+}$ uptake by glial cells was observed in this study at any extracellular MnCl$_2$ concentration or glial activation level or time.

The *in vivo* imaging study was designed to reveal the effects of microglial and astrocytic reactions on MEMRI signal enhancement. The imaging times of Day 1 and Day 7 were chosen because, after one day of LPS injection, microglial reaction is well defined, and astrocytic reaction generally takes place after three-four days, and becomes well established around seven days.

The *in vivo* study has clearly demonstrated the co-localization and strong correlation between reactive astrocytes and MEMRI signal enhancement. By incorporating the *in vitro* finding that reactive astrocytes stimulate neuronal manganese
uptake rather than absorb manganese themselves, we are confident to conclude that the MEMRI signal enhancement resulted from the elevated manganese uptake in neurons stimulated by astrocytic reaction.

In GFAP stained brain slices, we also found activated astrocytes in regions remote from the injection line in the LPS + Mn$^{2+}$ mice. However the number of the activated astrocytes in these regions was small. The neuronal Mn$^{2+}$ uptake caused by these astrocytes was not detected in MRI due to the limited sensitivity.

Several groups have studied the relationship between MEMRI signal enhancement and glial reaction in a range of animal models of human disease, including but not limited to, cathepsin D deficiency [26], epilepsy [8], ischemia [14,22,27] and prenatal X-ray exposure [9]. However, results have been varied. Some studies showed elevated MEMRI signal enhancement co-localized with activated microglia [26] or both activated microglia and astrocytes [14,22,27]. However the study of prenatal X-ray exposure [9] found negative correlation between brain tissue longitudinal relaxivity (R$_1$) and reactive astrocytes. Because R$_1$ determines MEMRI signal intensity, this study suggested that astrocytic reaction suppressed signal enhancement. Another study of epilepsy [8] found no correlation between MEMRI signal change and astrocytic reaction. The inconsistent results from these studies could be due to the variety of disease models used. In these diseases, a variety of pathobiological events occur in addition to glial reaction, such as cell swelling and necrosis [14,22,27], apoptosis [26], and hippocampal mossy fiber spouting [8]. These events can impair neurons that could either stimulate or suppress neuronal Mn$^{2+}$ uptake, causing inconsistent MEMRI signal enhancement. One particular study [24] using rats, found strong positive correlation between MEMRI signal
enhancement and astrocytic reaction in a stroke model, and proposed that the signal enhancement is caused by Mn$^{2+}$ accumulation in reactive astrocytes through voltage-gated Ca$^{2+}$ channels. However, this study did not investigate the neuronal reaction to glial activation, and thus cannot exclude the contribution of elevated Mn$^{2+}$ uptake by reactive neurons to signal enhancement.

Astrocytes react rapidly to various neurodegenerative insults. Reactive astrocytes protect neurons by secluding the injury site from the rest of the CNS area, and secreting multiple neurotrophic factors to aid neuronal survival. However, the astrocytic processes have been implicated in the pathogenesis of a variety of neurodegenerative diseases, including but not limited to, Alzheimer’s disease, Parkinson’s disease, HIV-associated neurocognitive disorders, acute traumatic brain injury, and inflammatory demyelinating diseases. It is believed that rapid and severe astrocytic reaction initiates or augments inflammatory response by secreting various pro-inflammatory molecules leading to neuronal death and brain injury [40].

Monitoring glial-neuronal interactions dynamically using noninvasive imaging technologies is a unique and powerful method, which can be used to understand the pathobiology of neurodegenerative diseases, provide diagnosis and prognosis, and aid in the development of therapeutic methods. MRI is a noninvasive imaging technology providing high spatial resolution, excellent soft tissue contrast and real-time measurements. Because Mn$^{2+}$ crosses the brain-blood barrier and enters neurons through voltage-gated calcium channels [41], MEMRI has proven to be a powerful tool to study neuronal viability, activation and impairment. The results in this study show the potential to use MEMRI monitoring of glial-neuronal interactions in normal and abnormal
conditions. Our immunohistological results showed no significant neuronal death caused by LPS injection at the times when MEMRI was performed. In the future we plan to extend the study to later stages at which neuronal death induced by glial reaction occurs. We expect to see decreased MEMRI signal enhancement due to the neuronal death as shown in several previous studies [10,11,13]. Therefore a longitudinal MEMRI study showing neuronal excitation by astrocytic reaction and neuronal death later provides valuable information of the progression of pathobiology.

In conclusion, we demonstrated that astrocytic reaction induces elevated neuronal Mn$^{2+}$ uptake that results in MEMRI signal enhancement. This study demonstrates that MEMRI can be used not only to monitor neuronal vitality and activity but also to monitor astrocyte-neuronal interactions in animal model systems of neurodegenerative diseases.
2.5. References


neurodegeneration, gliosis or seizure-activity in the epileptic rat hippocampus. Neuroimage. 40, 1718-1730.


distribution in glial cells cultured from chick cerebral cortex. Neurochem. Res. 14, 1129-
1135.

41, 79-87.


Disese, Nova Science Publisher, Inc., New York,.

CHAPTER - 3

Manganese-Enhanced Magnetic Resonance Imaging (MEMRI)

Detects Brain Pathology in Animal Models of Neurodegenerative Diseases
3.1. Introduction

HIV-1-associated neurocognitive disorders (HAND) is a clinical disorder that reflects the cognitive, behavioral and motor dysfunctions associated with progressive viral infection [1]. HAND reflects a spectrum of clinical abnormalities that include asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated dementia (HAD) [2]. Although antiretroviral therapy (ART) has significantly decreased the HAD incidence and prevalence, ANI and MND are seen in half of infected patients [3] and as such continues to be a significant quality of life complication of HIV/AIDS [4,5]. Despite advances in the understanding HIV neuropathobiology, disease diagnosis is made by exclusion of co-morbid conditions such as drug abuse, neurodegenerative and psychiatric disorders, opportunistic infections and malignancies [6]. Moreover, levels of viral replication and cognitive impairment are not always linked nor do they provide clear relationships between neuropathology and cognitive function [4]. It is possible that diagnostic clarity could be provided through imaging biomarkers.

In attempts to detail HIV-associated neuropathology, our laboratories pioneered the development of murine models of virus-associated brain disease [7]. Specifically, we show that humanized mice reconstituted with CD34+ human hematopoietic stem cells reflect the consequences of viral infection and consequent immune deterioration in its human host [8-11]. In this model, human progenitor cells are transplanted into genetically modified immunodeficient NOD/scid-IL-2Rγc null (NSG) mice [12]. Such mice support persistent HIV-1 infection leading to behavioral and motor impairments paralleling
neuronal and glial responses [13]. Our recent works demonstrated that brain imaging such as proton magnetic resonance spectroscopy (\(^1\text{H MRS}\)) and diffusion tensor imaging (DTI) can uncover the neuropathological consequences of chronic HIV-1 infection in these mice [8,13].

A significant advantage for manganese-enhanced magnetic resonance imaging (MEMRI) over other magnetic resonance imaging (MRI) modalities rests in the ability to directly map voltage-gated calcium channel activity through manganese ions (Mn\(^{2+}\)) neuronal accumulation. As Mn\(^{2+}\) is a calcium (Ca\(^{2+}\)) analogue, it can enter neurons by voltage-gated Ca\(^{2+}\) channels [14] and can be moved anterograde by axonal transport and microtubule assembly [15,16]. Mn\(^{2+}\) is an excellent T\(_1\) shortening contrast agent affording relatively high spatial resolution and signal-to-noise ratio within reasonable scanning time [17,18]. Administration of Mn\(^{2+}\) generates enhanced signal intensity on T\(_1\)-wt images. The signal enhancement is associated with neuronal activities. MEMRI can assess neuronal well-being for anatomical, integrative, functional and axonal transport activities of nerve cells and their connections [14,19]. Herein, we demonstrate that MEMRI facilitates precise noninvasive high spatial resolution (100 \(\mu\text{m}^3\) isotropic) determinations of brain regions of HIV-1 incited neuroinflammation and neuronal injury in NOD/scid-IL-2R\(\gamma_c\)null humanized mice. Correlations between immunocytochemical measures of brain disease and MEMRI signal enhancement are operative.

3.2. Materials and Methods

3.2.1. Murine neuroAIDS model
NOD/scid-IL-2Rγcnull (NSG) mice were bred under specific-pathogen-free conditions in accordance with the ethical guidelines at the University of Nebraska Medical center (UNMC), Omaha, Nebraska. Human cord blood obtained with parental written informed consent from healthy full-term newborns (Department of Gynecology and Obstetrics, UNMC) was utilized for CD34+ cells isolation using immune-magnetic beads according to the manufacturer's instructions (CD34+ selection kit; Miltenyi Biotec Inc., Auburn, CA). Numbers and purity of human CD34+ cells were evaluated by fluorescence-activated cell sorting (FACS). Cells were either frozen or immediately transplanted into newborn mice at $10^5$/mouse intrahepatically (i.h.) in 20 μl phosphate-buffered saline (PBS) using a 30-gauge needle. Newborn mice received human cells from single donors.

On the day of birth, newborn mice were irradiated at 1 Gy using a C9 cobalt 60 source (Picker Corporation, Cleveland, OH). Starting from 22 weeks after reconstitution, HIV-1 virus was intraperitoneally (i.p.) injected at $10^4$ TCID$_{50}$ into mice. Humanized mice without infection served as controls. Number of human cells and the level of engraftment were analyzed by flow cytometry. In the study, all protocols related to animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC), UNMC University and met the requirements of the UNMC University ethical guidelines, which are set forth by the National Institutes of Health.

3.2.2. Viral load

The automated COBAS Amplicor System V1.5 (Roche Molecular Diagnostics, Basel, Switzerland) was used to measure the peripheral level of viral RNA copies/ml. Mouse
plasma (20 µl) was used to dilute with 480 µl of sterile normal human plasma for the assay. The baseline detection of assay after dilution is 1250 viral RNA copies/ml.

3.2.3. Flow cytometry
Peripheral blood leukocytes, spleen and bone marrow cell suspensions were examined for anti-human-CD45, CD3, CD4 and CD8 markers. Flow cytometry on peripheral blood leukocytes was done every other week from the point of infection. At the end of study, flow cytometry was done for spleen and bone marrow as well. Mouse peripheral blood samples were collected from submandibular vein (cheek bleed) by using lancets (MEDIpoint, Inc., Mineola, NY) in EDTA coated tubes. Antibodies and isotype controls (BD Phar-Mingen, San Diego, CA) were used to stain cells. Staining was analyzed by using FACSDiva (BD Immunocytometry Systems, Mountain View, CA). Percentages of total gated lymphocytes were expressed as results.

3.2.4. Immunohistology
At 16 weeks, mice were euthanized immediately after imaging and brains were collected. Brain tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin. Five µm thick brain tissue sections were labeled with mouse monoclonal antibodies for HLA-DQ/DP/DR (1:100, Dako, Carpinteria, CA), HIV-1 p24 (1:10, Dako), c-Fos (1:50, Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonal antibodies for glial fibrillary acidic protein (GFAP) (1:1000, Dako), ionized calcium binding adaptor molecule -1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA), Caspase3 (1:10, EMD Millipore, Billerica, MA). The polymer-based HRP-conjugated anti-mouse and anti-
rabbit Dako EnVision systems were used as secondary detection reagents, and 3,3’-diaminobenzidine (DAB, Dako) was used as a chromogen. All paraffin-embedded sections were counterstained with Mayer’s hematoxylin. Deletion of primary antibodies served as controls. Images were captured with a 100×, 40× and 20× objectives using Nuance EX multispectral imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY).

For immunofluorescence labeling, brain sections were treated with the paired combination of primary antibodies mouse anti-synaptophysin (SYN) (1:1000, EMD Millipore), and rabbit anti-microtubule-associated protein 2 (MAP2) (1:500, EMD Millipore), mouse anti-neurofilament (NFs) (1:200, Dako) and rabbit anti-GFAP (1:1000, Dako); additionally, brain sections were treated alone with rabbit anti-Iba-1(1:500). Primary antibodies were labeled with secondary anti-mouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and nuclei were labeled with DAPI (4,6-diamidino-2-phenylindole). Slides were cover-slipped with ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA). Slides were stored at −20 °C after drying for 24 hours at room temperature. Images were captured at wavelengths encompassing the emission spectra of the probes, with a 40× objective by Nuance EX multispectral imaging system fixed to a Nikon Eclipse E800 and image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) was used for quantification of SYN, MAP2, NF and GFAP expression. Area-weighted average fluorescence intensity was calculated in the region of interest (ROI) by dividing the total signal intensity, for each partitioned area, by area (µm²) as intensity/µm². Images were also captured with LSM 710 microscope using a 40X oil lens (Carl Zeiss Microscopy,
LLC, NY, USA). Expression of cFos was scored (out of 10) by two investigators using 20× objective in blinded manner. Findings were compared to animals that were not manipulated (score 0). Student’s t-tests were performed to compare immunohistological results of the HIV-1 infected animals with controls.

3.2.5. MEMRI

MnCl$_2$·4H$_2$O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl (Hospira, Lake forest, IL) to make 50 mM MnCl$_2$ solution. MnCl$_2$ solution was administrated i.p. with the dose of 60 mg/kg consecutively four times at 24 hour intervals before MRI. After the injection, the mouse was observed daily to detect the side effects of MnCl$_2$.

MRI data were acquired 24 hours after the last MnCl$_2$ administration on Bruker Bioscan 7 Tesla/21 cm small animal scanner (Bruker, Billerica, MA) operating Paravision 5.1 with a 72 mm volume resonator and a 4-channel phased array coil. Mice were anesthetized by inhalation of isoflurane in 100% oxygen and maintained 40-80 breaths/minute. Mice were scanned using T$_1$ mapping sequence (fast spin echo with variable repetition time (TR) from 0.4 s to 10 s, 12 slices, slice thickness = 0.5 mm, in-plane resolution = $0.1 \times 0.1$ mm$^2$) and T$_1$-wt MRI (FLASH, TR = 20 ms, flip angle = $20^\circ$, 3D isotropic resolution = $0.1 \times 0.1 \times 0.1$ mm$^3$). After MRI, the mice were euthanized and tissues were removed for immunohistological study. The same scan was also performed before the MnCl$_2$ administration, and the acquired image was used as baseline data for the calculation of signal enhancement.

3.2.6. MRI data pre-processing
To reduce the influence of the inhomogeneous signal reception on the T\textsubscript{1}-wt images by the phased array surface coil, N3 field inhomogeneity correction [20] was first performed on each image using MIPAV (CIT, NIH). The brain volumes in the T\textsubscript{1}-wt images were extracted using an in-house Matlab program [21] based on the level sets method. The brain images were then registered to a MEMRI-based NSG mouse brain atlas developed in our laboratories using affine transformation first, and then nonlinear transformation (DiffeoMap, John Hopkins University, Baltimore, MD).

To calculate Mn\textsuperscript{2+} induced T\textsubscript{1}-wt signal enhancement, the MRI system variations between the baselines and post MnCl\textsubscript{2} injection scans need to be minimized. This is achieved by calibrating the baseline and post Mn\textsuperscript{2+} injection T\textsubscript{1}-wt images using T\textsubscript{1} values. A detailed description of the MEMRI enhancement calculation and T\textsubscript{1}-wt image calibration are described in the MEMRI signal enhancement and tissue manganese concentration part of the methods and material section of this chapter. The T\textsubscript{1} maps were first generated using an in-house Interactive Data Language (IDL) version 8.2 (Exelis Visual Information Solutions, Boulder, Colorado) program from the data acquired by T\textsubscript{1} mapping sequence. ROIs were then placed on relatively uniform tissue regions including frontal cortex and caudate on T\textsubscript{1} maps and T\textsubscript{1}-wt images. The baseline and post Mn\textsuperscript{2+} injection longitudinal relaxivity (R\textsubscript{1bl}\textsuperscript{ROI} and R\textsubscript{1Mn}\textsuperscript{ROI}) and T\textsubscript{1}-wt signal intensity (S\textsubscript{bl}\textsuperscript{ROI} and S\textsubscript{Mn}\textsuperscript{ROI}) in the ROIs were measured. The calibration factor was calculated as $C = (S\textsubscript{Mn}^{ROI}/S\textsubscript{bl}^{ROI}) \times (R1\textsubscript{1bl}^{ROI}/R1\textsubscript{Mn}^{ROI})$. The baseline T\textsubscript{1}-wt image (S\textsubscript{bl}) was then calibrated using the calibration factor $C$: $S\textsubscript{bl}^{C} = S\textsubscript{bl} \times C$.

3.2.7. MEMRI signal enhancement and tissue manganese concentration
In this study, MEMRI enhancement is defined as $(S_{Mn} - S_{bl})/S_{Mn}$, where $S_{bl}$ and $S_{Mn}$ are the baseline (bl) and manganese enhanced (Mn) signal, respectively. The spoiled FLASH (Fast Low Angle SHot) sequence was used to acquire $T_1$-wt images in this study. The signal generated using FLASH can be expressed as:

$$S = M_0 \frac{\sin(\alpha(1-e^{-\frac{TR}{T_1}}))}{1-\cos(\alpha e^{-\frac{TR}{T_1}})} e^{-\frac{TE}{T_2}}$$

(1),

where $M_0$ is the spin density, TR and TE are repetition and echo time, respectively. $\alpha$ is the flip angle. Therefore, the baseline and manganese enhanced signal are

$$S_{bl} = M_0 \frac{\sin(\alpha(1-e^{-\frac{TR}{T_1}}))}{1-\cos(\alpha e^{-\frac{TR}{T_1}})} e^{-\frac{TE}{T_2}}$$

(2),

and

$$S_{Mn} = M_0 \frac{\sin(\alpha(1-e^{-\frac{TR}{T_1Mn}}))}{1-\cos(\alpha e^{-\frac{TR}{T_1Mn}})} e^{-\frac{TE}{T_2}}$$

(3).

The ratio of the manganese enhanced and baseline signals is

$$\frac{S_{Mn}}{S_{bl}} = \frac{(1-e^{-\frac{TR}{T_1Mn}}) e^{-\frac{TE}{T_2}}}{(1-e^{-\frac{TR}{T_1bl}}) e^{-\frac{TE}{T_2}} \cdot (1-\cos(\alpha e^{-\frac{TR}{T_1}}))}$$

(4).

$T_2$ reduction caused by manganese administration is much less pronounced than $T_1$ reduction. A previous study showed that in rat cortex, the $T_2$ reduction is about 10% at 24 hours after MnCl$_2$ injection, while $T_1$ reduces approximately 30% (Chuang KH et al., Magnetic Resonance in Medicine, 2009, doi: 10.1002/mrm.21962, PMID:19353652). TE is also relatively short as well (=3 ms) in this study. Therefore Eqn (5) can be simplified as

$$\frac{S_{Mn}}{S_{bl}} = \frac{(1-e^{-\frac{TR}{T_1Mn}}) e^{-\frac{TE}{T_2}}}{(1-e^{-\frac{TR}{T_1bl}}) e^{-\frac{TE}{T_2}} \cdot (1-\cos(\alpha e^{-\frac{TR}{T_1}}))}$$

(5).

Recall the Taylor expansion:

$$e^x = 1 + x + \frac{x^2}{2!} + \frac{x^3}{3!} + ...$$

(6).
Replace $x$ with $(-TR/T_1)$ in Eqn (6):

$$e^{-TR/T_1} = 1 + (-TR/T_1) + \frac{(-TR/T_1)^2}{2!} + \ldots,$$  \quad (7)

and since $TR (= 20 \text{ ms}) / T_1 (> 800 \text{ ms in most regions after manganese administration})$ is small, the second and higher order terms in Eqn (7) can be ignored, that is, $e^{-TR/T_1} \approx 1 + (-TR/T_1)$. Applying this equation in Eqn (5) and after skipping several steps, Eqn (5) can be further simplified:

$$\frac{S_{Mn}}{S_{bl}} = \frac{(TR/T_{2Mn})(1-cosa+cos(a(TR/T_{1bl})))}{(TR/T_{1bl})(1-cosa+cos(a(TR/T_{2Mn})))}.$$  \quad (8)

The third terms in both numerator and denominator are at the second order, and thus can be dropped similarly to in Eqn (7):

$$\frac{S_{Mn}}{S_{bl}} = \frac{T_{1bl}(1-cosa)}{T_{2Mn}(1-cosa)} = \frac{R_{1Mn}}{R_{1bl}} \quad \text{(9)},$$

where $R_l$ is the relaxivity, and $R_I = 1/T_I$. Eqn (9) means that the ratio of the signals acquired before and after manganese administration is equal to the ratio of relaxivities.

As $R_{1Mn} = R_{1bl} + r_1[Mn]$, where $r_1$ is the molar relaxivity (s$^{-1}$ mM$^{-1}$) of manganese, and $[Mn]$ is the manganese concentration in mM, Eqn (9) can be rewritten as

$$\frac{S_{Mn}}{S_{bl}} = \frac{R_{1bl}+r_1[Mn]}{R_{1bl}} = 1 + \frac{r_1[Mn]}{R_{1bl}} \quad \text{(10)}.$$  

Replacing 1 with $S_{bl}/S_{bl}$ and subtracting one from each side:

$$\frac{S_{Mn}-S_{bl}}{S_{bl}} = \frac{r_1[Mn]}{R_{1bl}} \quad \text{(11)}.$$  

From Eqn (11), we can see the tissue manganese concentration $[Mn]$ is proportional to the normalized signal change induced by manganese administration (i.e., the signal enhancement).
MRI scanner system calibration:

System settings such as RF coil, analogue-to-digital converter, and environment temperature can change in the post-manganese administration imaging session from the pre-administration session. The variation can be minimized by calibrating the system using relaxation times measured before and after manganese administration. If we assume that the effect of the system variation is a constant $C$ (calibration factor) and set system parameter of the post-manganese session as 1, then the acquired baseline signal is $S_{acq} = CS_{bl}$. From Eqn (9),

$$C = \frac{S_{acq}}{S_{Mn}} \cdot \frac{T_{bl}}{T_{1Mn}}$$  \hspace{1cm} (12).

$T_{bl}$ and $T_{1Mn}$ were measured using a fast spin echo sequence with variable TR in this study. Using $C$ from Eqn (12), $S_{bl}$ can be calculated: $S_{bl} = S_{acq} / C$.

3.2.8. MEMRI enhancement analysis

The Mn$^{2+}$ induced $T_1$-wt signal enhancement was calculated by: $(S_{Mn} - S_{bl}^C) / S_{bl}^C$. A pixel-by-pixel comparison was first performed between the HIV-1 infected mice and the control group using Student’s t-test, followed by a brain region specific analysis. Using the MEMRI-based brain atlas, the $T_1$-wt signal enhancement on 41 brain regions/sub-regions was calculated. The student’s t-test was performed to exam the significance of enhancement change in each HIV-1 infected brain region compared to the control group.

The association between MRI signal changes, plasma viral load, T-cells and immunohistological results in HIV mice was examined using Pearson product-moment correlation. The association between enhancement and quantified GFAP, Iba-1, MAP2, NF and SYN staining was studied on the CA1, CA3 and DG brain regions. Time course of infection that included measures of the plasma viral load at the time of animal sacrifice
(16 WPI), its rate of change (slope) over time, and change in maximum and end time viral levels were measured. These parameters tested over time were correlated with MRI signal enhancements. The T-cell parameters that were measured over time included blood, spleen and bone marrow CD4 and CD8 positive T cell numbers.

3.2.9. Brain structure volumetric analysis

In the MRI data pre-processing, the brain images were registered to the MEMRI-based brain atlas. The 41 brain regions were identified on each brain image. The brain images were transferred back to their original spaces employing the inverse of the transformation matrices calculated for registration. The volumes of the regions were calculated in the original spaces. Student’s t-tests were performed to compare the volumes of the HIV-1 infected animals with controls.

3.2.10. Detection of Mn$^{2+}$ toxicity

Animals were observed daily after each i.p. MnCl$_2$ injection and 24 hours after the injection. If tremor or convulsion (the signs of manganese overdose) persisted longer than 3 minutes or lethargy observed at 24 hours, mice were euthanized.

3.3. Results

3.3.1. HIV-1 Infection of humanized mice

Humanized mice (n = 8) were infected with the HIV-1$_{ADA}$ at 22 weeks of age (Fig. 3.1.a). Viral and immune parameters were assessed then compared against controls (uninfected humanized mice, n = 7). Flow cytometry was performed at 2, 4, 7, 10, 13 and 16 weeks
post infection (WPI) to determine reconstitution of peripheral human immune cells (CD45, CD3, CD4, CD8). The temporal changes of CD4+ and CD8+ T cells in infected humanized mice are shown in Fig. 3.1.b. The steady CD4+ T cells decline and concomitant increases in CD8+ T cells were readily seen in HIV-1 infected mice. Control uninfected animals showed no changes in T cell numbers throughout the study period (Fig. 3.1.b). Plasma viral RNA copies/ml (viral load, VL) measures were performed at 2, 7, 16 WPI (Fig. 3.1.c). These VL values peaked at the 2nd week after HIV-1 infection and were sustained throughout the experimental observation period.

3.3.2. Leukocyte brain infiltration

Brain infiltration of human cells including those HIV-1 infected were assessed by immunohistochemical assays. At 16 WPI, brain sections at 5 µm thickness were stained for human HLA-DR and HIV-1p24. Human HLA-DR+ cells infiltrated the brains of infected and control mice were seen in the meninges and perivascular spaces (Fig. 3.1.d). Few HIV-1p24+ human cells were observed in these regions of infected mice (Fig. 3.1.e). Glial responses were assessed by glial fibrillary acidic protein (GFAP, astrocyte) and ionized calcium binding adaptor molecule-1 (Iba-1, microglia) staining. Cortical areas with hypertrophic astrocytes and morphological features of activated microglia were readily observed (Fig. 3.1.f). Such activated glial morphologies were not seen in control animals.

3.3.3. MEMRI
To track neuropathology induced by continuous HIV-1 infection, MEMRI was performed at 16 WPI (Fig. 3.1.a). The averaged MEMRI image of the control mice is shown on coronal brain slices as an anatomical reference in the left column of Figure 3.2.a. Positions of the coronal slices are depicted using a sagittal slice (top of the left column). Standard tissue signal enhancement induced by Mn^{2+} was readily seen within the olfactory bulb, cerebral cortex, hippocampus, and cerebellum [19]. The color-coded average enhancement maps of the control and HIV-1 infected mouse brains are illustrated in the second and third columns of Figure 3.2.a, respectively. The enhancement represented the signal change induced by Mn^{2+} normalized to the MRI signal of pre-Mn^{2+} administration. MEMRI enhancement changes were observed throughout the brain in HIV-1 infected animals compared to controls (Fig. 3.2.a). Statistically significant increases in the MEMRI enhancement are shown by pixels with p < 0.05 (the first column in Fig. 3.2.b). These p values are color-coded and overlaid on the averaged MEMRI slices. Using the MEMRI-based mouse brain atlas, 41 brain regions/sub-regions were identified for each humanized mouse. A list of regions on the brain atlas can be found in chapter 4 (Table 4.1). The MEMRI enhancement was compared between each brain region of control and HIV-1 infected mouse. The regions with p values less than 0.05 from such comparisons are shown in the second column in Figure 3.2.b and illustrated with identical color-coding as in the first column. The brain regions with significantly increased signal enhancement (p < 0.05) are also included within Table 3.1. Three-dimensional images of brain regions with significant enhancement increase are illustrated in Figure 3.2.c. The brain regions showing trends of enhancement increase are listed in Table 3.2. Morphological and volumetric changes were assessed in virus-
infected animals by the MEMRI mouse brain atlas. Whole brain and regional volumes in the HIV-1 infected mice were comparable to control animals (data not shown). The toxicity of Mn$^{2+}$ was considered. Mice were observed daily after i.p. MnCl$_2$ injections. This included chemical injection linked tremor and lethargy, the clinical signs of Mn$^{2+}$ overdose. No Mn$^{2+}$ induced toxic signs and symptoms were observed during the study.

3.3.4. Immunohistology

Immunohistochemistry was subsequently performed on CA1, CA3 and the dentate gyrus (DG) regions of the hippocampus at study termination, 16 WPI (Fig. 3.1.a). Brain sections were stained for GFAP, Iba-1, cFos (neuronal activation), synaptophysin (SYN, synaptic vesicle protein), and neurofilament (NF, neuronal cytoskeleton protein). Fluorescence intensity for these antigens was expressed as intensity/µm$^2$. Activated morphologies were observed as defined by increased cell body size and process formations for both astrocytes and microglia in virus-infected animals (Fig. 3.3.a and 3.3.b). The presence of activated astrocytes and microglia are known to be linked to virus-induced inflammation [22,23]. Neuronal activation (cFos expression) was substantially higher in brain regions with gliosis and specifically in the hippocampus; indicating increased neuronal excitation during inflammation (Fig. 3.3.c, Fig. 3.5). Irregularly shaped and decreased SYN expression was seen in the CA3 region of infected animals and reflected synaptic injury (Fig. 3.3.d). Reduction in NF fibers was also observed at CA3 region in infected animals (Fig. 3.3.e). NF and SYN expression demonstrates neuronal injury after glial inflammation. Co-localized MEMRI enhancement in infected animals was compared to controls and confirmed the sensitivity
of the MEMRI in reflecting glial and neuronal histochemical and morphological changes (Fig. 3.3.f).

Quantitative immunohistochemistry was used to compare neuropathology between control and HIV-1 infected mice and its association with MEMRI regional enhancements. In CA1 region, GFAP and Iba-1 expression were significantly higher in infected animals than controls (GFAP, p = 0.041; Iba-1, p = 0.018); whereas, SYN and NF expression were not different amongst the groups (Fig. 3.4.a). Gliosis with no evidence of neuronal injury in CA1 paralleled significant MEMRI signal enhancement increase in infected animals compared to controls (p = 0.047) (Fig. 3.4.a). In the CA3 region, GFAP expression was higher (p = 0.038), and SYN and NF expression lower (SYN, p = 0.027; NF, p = 0.005); whereas, Iba-1 signals were not changed by viral infection (Fig 3.4.b). With a combination of astrocyte responses and neuronal injury, MEMRI signal remained similar between infected and control animals (Fig. 3.4.b). GFAP expression was higher (GFAP, p = 0.042) and Iba-1 increased but not significantly (Iba-1, p = 0.083) in the DG region of infected animals; whereas SYN and NF signals were not changed (Fig. 3.4.c). MEMRI enhancement in this region was increased in infected animals (p = 0.045) (Fig. 3.4.c). The quantitative analyses taken together, demonstrate that activated glia and neurons (increased cFos staining) during inflammation induced the increase in MEMRI signal in the CA1 and DG brain regions. However, the enhancement increase was offset by neuronal injury (reduced SYN and NF) in the CA3 brain region. Microtubule associated protein (MAP2) staining was not changed in the infected animals. Evidence for neuronal apoptosis determined by anti-caspase3 staining was not observed in infected mice (data not shown).
We next investigated if glial activation and MEMRI signal enhancements were correlated one with the other. In the CA1 and DG, correlations between GFAP expression and MEMRI signal increase were seen (CA1, $r = 0.86$, $p = 0.007$; DG, $r = 0.92$, $p = 0.001$). Linkages between gliosis and MEMRI enhancement demonstrated that $\text{Mn}^{2+}$ uptake and accumulation increases in neurons affected by inflammation. This was associated with astrocyte responses and the MEMRI signals [24]. Next we measured relationships between the degree of brain injuries and VL in blood. The average brain MEMRI enhancement alteration was linked, in measure, to the peripheral VL difference of at 16 weeks and maximum values (defined as viral load dynamics; $r = 0.714$, $p = 0.071$). This result suggested that the greater the viral load drop during the course of infection, the smaller the MEMRI enhancement change. MEMRI enhancement was not affected by numbers of CD4+ and CD8+ T cells (data not shown).
Figure 3.1. (a) The time course of human CD34+ cell reconstitution, HIV-1 infection, MRI, MnCl₂ injections and histopathology. (b) Results from flow cytometric analyses of human CD4+ and CD8+ cells in peripheral blood of control mice (left) and infected mice (right). (c) Average HIV-1 RNAs (copies/ml) in peripheral blood of infected mice (n = 8). (d and e) Infiltration of human activated cells detected by HLA-DR (indicated by arrows, left, 20x) and HIV-1+ cells (detected by p24 antigen) in meninges, parenchyma.
and perivascular spaces (positive cells indicated by arrows, right, 100×) into the brain of infected mice at 16 WPI. (f) Brain sections of control and infected mice stained by GFAP for astrocyte (left, 40×) and by Iba-1 for microglial (right, 40×). Activated glial cell morphologies were seen in infected animals. Data are expressed as mean ± SEM in (B) and (C).
(a) 

Control

HIV-1
(b) p-value map

Significantly altered regions

p-value map

Significantly altered regions

0.05
0.00
**Figure 3.2.** Comparison of MEMRI enhancement between HIV-1 infected animals and controls. (a) MEMRI enhancement maps. The first column (from left) shows coronal slices of the averaged MEMRI of control mice as an anatomical reference. The sagittal slice (upper left) shows respective coronal positions (red lines). The second column shows the average enhancement in control mice on the coronal slices. The third column represents the average enhancement of HIV-1 infected mice. The color bar for the enhancement maps is at the top of the figure. Dark blue color (0%) means no change in enhancement from Mn$^{2+}$ compared to pre-injection signal intensity. Dark red color represents 120% signal increase compared to pre-injection. Increase in MEMRI enhancement can be seen throughout the brain of infected animals than controls. (b) Statistical comparison of MEMRI enhancement between control and HIV-1 infected animals. The left column shows the pixels with significant enhancement difference (p < 0.05) overlaid onto the averaged brain image. The color bar of p values is at the right. Dark blue color represents p = 0.05 and dark red color represents the value of 0.00. The right column shows significantly altered brain regions of infected mice using the same color scale. (c) Brain regions with significant enhancement changes demonstrated in 3-D. (1) Averaged brain image. (2) Right hemisphere of the averaged brain. Internal brain regions can be seen on the middle of sagittal section. (1 and 2) are to provide anatomical references for the demonstration of regions with significant enhancement changes. (3) Sub-cortical regions including CA1_CA3_SUB (red) and CP (green). (4) Sub-cortical regions including DG-mo (red), AMY (orange), PALc (green), and GP (yellow). (5) Brain stem regions including TH (red), EPI (green), SN (blue) and PRT (purple). (6) PAG (blue), IC (yellow), SN (red) and PRT (purple). (7) Olfactory regions including
MOB (red), AOB (green), AON (blue) and PIR (yellow). (8) cc (red) and CBXmo (blue).

The full names of the brain regions are included in Table 3.1.
Table 3.1. Brain regions that showed significant signal enhancement (p < 0.05)

<table>
<thead>
<tr>
<th>Brain regions</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA1_CA2_SUB</td>
<td>0.047</td>
</tr>
<tr>
<td>DG-mo</td>
<td>0.046</td>
</tr>
<tr>
<td>CP</td>
<td>0.039</td>
</tr>
<tr>
<td>AMY</td>
<td>0.048</td>
</tr>
<tr>
<td>GP</td>
<td>0.028</td>
</tr>
<tr>
<td>PALc</td>
<td>0.047</td>
</tr>
<tr>
<td>TH</td>
<td>0.03</td>
</tr>
<tr>
<td>EPI</td>
<td>0.043</td>
</tr>
<tr>
<td>P</td>
<td>0.044</td>
</tr>
<tr>
<td>PAG</td>
<td>0.022</td>
</tr>
<tr>
<td>IC</td>
<td>0.01</td>
</tr>
<tr>
<td>SN</td>
<td>0.041</td>
</tr>
<tr>
<td>RMB</td>
<td>0.033</td>
</tr>
<tr>
<td>PRT</td>
<td>0.043</td>
</tr>
<tr>
<td>MOBgl</td>
<td>0.021</td>
</tr>
<tr>
<td>AOB</td>
<td>0.012</td>
</tr>
<tr>
<td>PIR</td>
<td>0.046</td>
</tr>
<tr>
<td>AON</td>
<td>0.036</td>
</tr>
<tr>
<td>CBXmo</td>
<td>0.031</td>
</tr>
<tr>
<td>cc</td>
<td>0.037</td>
</tr>
</tbody>
</table>

Table 3.2. Brain regions that showed trend of signal enhancement increase

(0.05 <= p < 0.01)

<table>
<thead>
<tr>
<th>Brain regions</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isocortex</td>
<td>0.06</td>
</tr>
<tr>
<td>Sub-cortical region</td>
<td></td>
</tr>
<tr>
<td>STRv</td>
<td>0.065</td>
</tr>
<tr>
<td>LSX</td>
<td>0.053</td>
</tr>
<tr>
<td>MS</td>
<td>0.055</td>
</tr>
<tr>
<td>DG-(po+sg)</td>
<td>0.071</td>
</tr>
<tr>
<td>Brain stem region</td>
<td></td>
</tr>
<tr>
<td>HY</td>
<td>0.074</td>
</tr>
<tr>
<td>MY</td>
<td>0.051</td>
</tr>
<tr>
<td>Cerebellar region</td>
<td></td>
</tr>
<tr>
<td>CBXgr</td>
<td>0.053</td>
</tr>
<tr>
<td>CBwm</td>
<td>0.07</td>
</tr>
<tr>
<td>FN</td>
<td>0.071</td>
</tr>
</tbody>
</table>

Isocortex, STRv: Striatum ventral region, LSX: Lateral septal complex, MS: Medial septal nucleus, DG-(po+sg): Dentate gyrus (polymorph layer + granular layer), HY: Hypothalamus, MY: Medulla, CBXgr: Cerebellar granular layer, CBwm: Cerebellar white matter, FN: Fastigial nucleus
Figure 3.3. Immunohistology of the hippocampus sub-regions including CA1, CA3 and DG (40×). Representative brain sections of control and HIV-1 infected mice stained for GFAP (astrocyte), Iba-1 (microglia), cFos (neuronal activation), SYN (synaptic vesicle protein), NF (neuronal cytoskeleton protein) and co-localized MEMRI slices are presented. (a, b and c) Increase in GFAP, Iba-1 and cFos expression was observed in infected animals compared to controls in all three regions of hippocampus. (d and e) In CA3 region, SYN and NF expression was decreased (indicated by an oval and arrows, respectively) of infected animals compare to controls, but not in CA1 or DG. (f) Altered in MEMRI enhancement in co-localized brain slices was observed in infected animals.
Figure 3.4. Association of immunohistology with MEMRI. (a) Quantitative analysis showed significant increase in GFAP, Iba-1, and MEMRI enhancement on CA1 region of HIV-1 infected animals compared to controls. (b) CA3 region showed significantly increased GFAP, significantly decreased SYN as well as NF, and no change in MEMRI signal in infected animals compared to controls. (c) DG region showed significantly increased GFAP, a trend of increased Iba-1, and significantly increased MEMRI enhancement in infected animals compared to controls. Data are expressed as mean ± SEM. (*: p < 0.05, #: p < 0.1)
Figure 3.5. cFos expression at hippocampus region. HIV-1 infection caused significant increase in cFos expression compared to control. Data are expressed as mean ± SEM. (*: p < 0.05)
C. HIV-1 (●) Infected Humanized Mouse Brain

- Pro-inflammatory cytokines, chemokines
- HIV-1 proteins (gp120, Tat, Vpr)
- iNOS
- Quinolic acid
- Arachidonic acid
- Glutamate

D. HIV-1 induced neuropathology, Mn²⁺ (●) accumulation and associated MEMRI signal enhancement
Figure 3.6. The mechanism of MEMRI in the detection of neuropathology in HIV-1 infected humanized mice. (a) Human immune system reconstitution (humanization) in NSG mouse. Human CD34+ stem cells (HSC) isolated from umbilical cord blood were injected intrahepatically into one day old irradiated pups. The injected HSC reach mouse lymphoid organs including bone marrow and develop into broad range of cell lineages. A mature human immune system develops in the NOD/scid-IL-2Rγcnull (NSG) mice. (b) Humanized mouse brain. Human cells (macrophages, yellow color) are majorly observed at meninges and perivascular spaces in humanized mouse brain. Mouse cells (resting glia and neurons) are showed in green colors. (c) HIV-1 infected humanized mouse brain. Infected human macrophages carry HIV-1 (green) into the brain and release pro-inflammatory cytokines, chemokines viral proteins, that leads to activated glia (red) followed by neuronal excitation (blue) and injury (gray). (d) HIV-1 induced neuropathology, Mn$^{2+}$ accumulation and associated MEMRI signal enhancement. Mn$^{2+}$ (blue and pink circle) enters brain through choroid plexus. Being Ca$^{2+}$ analog, it enters neurons through voltage gated Ca$^{2+}$ channels. Mn$^{2+}$ is transported anterogradely by microtubule assembly. Once Mn$^{2+}$ is released, it is taken up by post-synaptic neurons. Mn$^{2+}$ accumulation increases in activated neurons during inflammation resulting in MEMRI signal enhancement increase (stronger purple outer glow compared to control). Whereas, Mn$^{2+}$ uptake and transportation are reduced in injured neurons and thus MEMRI signal is suppressed.
3.4. Discussion

Humanized mouse model (NSG/CD34+) of HIV/AIDS can, in part, mirror human HIV-1 associated neuropathology [8,9,13] and was used successfully to test ART efficacy [25]. Peripheral VL and human CD4+ T-cell decline are hallmarks of HIV-1 infection in humans which are reflected in these humanized mice. Moreover, a metabolic encephalopathy caused by viral infection resulting in micro- and astro- gliosis, myelin pallor, excitotoxicity and neuronal injury is also seen in both humans and infected mice [8,9,13,22]. Such spectrums of pathologies make the humanized mice a relevant model for study. In the present study, altered MEMRI brain signal is seen in HIV-1 infected mice that serve to assess the complexities of neuropathology that underlie HAND’s clinical manifestations. Although, MEMRI was used previously to study a range of neurodegenerative disease models [26-29], this is the first report of its use to study effect of HIV-1 on humanized mice brain function and anatomy with improved analytical method.

MEMRI enhancement for HIV-1 infection is linked to reactive astrocytes and activated neurons. The cellular basis of the enhancement change was investigated in a previous study and interpreted as elevated neuronal Mn$^{2+}$ uptake and accumulation stimulated by astrocyte activation [24]. The associations between MEMRI signal with reactive astrocytes and neuronal responses was previously observed [24,29,30]. We previously showed that activated glia do not accumulate excessive Mn$^{2+}$ but stimulate neuronal Mn$^{2+}$ uptake [24]. Thus, MEMRI can be used to monitor virus-associated neuronal excitotoxicity that occurs as a consequence of neuroinflammation. In the CA3 region, both inflammation and neuronal injury (synaptic and axonal injury) were
operative in the infected animals. This is consistent with the fact that neuronal damage caused by HIV-1 infection begins with synaptic damage, compromised dendrite arbor, then neuronal death occurs as a consequence of persistent infection and immune deterioration [31]. Interestingly, in CA3 region, we did not observe MEMRI signal increase as in CA1 and DG. Indeed, damaged neurons likely influence reduction in neuronal Mn$^{2+}$ accumulation. The voxel size of MEMRI was 100 µm$^3$, which contains a large number of cells. The MEMRI enhancement of each voxel resulted from the combining effects of activated and injured neurons. Simply, the MEMRI signal enhancement induced by activated neurons was likely offset by signal decrease in injured cells. Increasing spatial resolution can partially solve the problem as excited and injured neurons may be differentiated. Additionally, performing MEMRI and immunohistological analysis at multiple time points after the infection may also establish accurate associations between signal enhancements and neuronal injury.

The cellular mechanisms underlying MEMRI enhancement is summarized in Figure 3.6. Humanized mice permanently carry human blood cells, and these populate brain primarily at meninges and perivascular spaces. After HIV-1 infection, infected human monocyte-macrophages carry HIV-1 into the brain and release pro-inflammatory cytokines, chemokines, viral proteins. This leads to activation of murine glia followed by neuronal excitotoxicity and injury, which in turn reflects the brain injuries seen as a consequence of chronic HIV-1 infection. Systemically administrated Mn$^{2+}$ enters the brain through choroid plexus. As a Ca$^{2+}$ analog, it enters neurons through voltage gated Ca$^{2+}$ channels and is transported anterogradely by microtubule assembly. Once Mn$^{2+}$ is released, it is taken up by post-synaptic neurons. Reactive astrocytes that arise as a
consequence of HIV-1 induced neuroinflammation first cause elevated neuronal Mn$^{2+}$ uptake resulting in increased MEMRI signal enhancement. Neuroinflammation then results in neuronal injury with consequently suppressed MEMRI signal.

In our parallel works, behavioral tests were used to show memory loss and cognitive dysfunction in these infected mice [13]. As the hippocampus plays an important role in memory and cognition, the glial activation and neuronal injury in this brain region detected in this study may contribute to such behavioral abnormalities. Aside from the hippocampus, the brain regions that show MEMRI signal enhancement following HIV-1 infection include sub-regions of the olfactory system, sub-cortical, brain stem and cerebellar regions. These findings suggest that infected mice can suffer motor and autonomic nervous system dysfunction because of cerebellar and brain stem damage. As different parts of the brain have variable vulnerabilities to HIV-1 infection [32,33], the current study provides a unique opportunity for unbiased mapping of region specific neuropathology.

The MEMRI results are supported by the DTI measures in our parallel study [13]. This study showed altered DTI parameters on hippocampal regions in HIV infected humanized mice, and association between the DTI parameters and quantitative histology. In infected human and nonhuman primates, abnormal DTI was found in the frontal and parietal white matter, putamen, and corpus callosum indicating neuroinflammation and axonal/myelin injury [34,35]. In parallel, inflammation metabolic abnormalities were detected by MRS in the basal ganglia, cerebrum, caudate, thalamus, and hippocampus [34-36]. We acknowledge that a direct comparison of the brain imaging findings in humans and nonhuman primates with mice is difficult due to differences in anatomy,
physiology, and neurochemistry. Our results are consistent with these human and non-human primate studies.

It is likely that abnormalities seen in these animals were not primarily a result of active viral replication in nervous system, but largely a consequence of replication in blood and peripheral lymphoid organs. Until now, studies have shown that peripheral blood nadir CD4+ T-cells count and viral DNA are systemic predictors of HIV-1 induced neurocognitive disorders [3,37,38]. However, we did see a trend towards correlation between MEMRI signal enhancement alteration and a plasma viral load measure, which is the difference between the maximum value and at 16 WPI. A parallel study found that viral levels correlated with cortical lactate [13]. The same study also found the correlation or the trend of correlation between cortical and dentate gyrus DTI parameters and viral load. Their study along with ours suggested that peripheral viral load might be associated with the neuropathology reflected by imaging in HIV-1 infected humanized mice. Such a sensitivity of the brain to peripheral events in these animals indicates a dynamic pathogenic process; where HIV-1 infected blood cells enter into the brain and cause disease [39].

We now demonstrate that MEMRI is a sensitive biomarker of HIV-1-induced neuropathology. However, when inflammation and neuronal impairment occur simultaneously, both increase and decrease in MEMRI signal can be observed. In order to improve the specificity of imaging on neuropathology, it is reasonable to combine MEMRI with other imaging modalities. For example, another study showed that the cerebral cortex is a primary region of damage in infected mice as demonstrated by MRS and DTI [13]. Combining MEMRI with MRS and DTI can positively determine
neuroinflammation (increased MEMRI enhancement and increase in myoinositol), and may help to detect neuronal impairment (reduced MEMRI enhancement, loss of N-acetylaspartate and creatine, reduced diffusivity, and fractional anisotropy). This package of imaging modalities will greatly enhance our ability for non-invasive assessment of HIV-1 induced neuropathology. In addition to assessment of neuronal Mn$^{2+}$ uptake, MEMRI can provide precise anatomical details. To this end, we applied a MEMRI-based NSG mouse brain atlas to assess brain morphology to reveal abnormalities associated with HIV-1 infection in an animal study. As we expected, we did not find changes in total brain and sub-structural volumes with altered MEMRI enhancement. This suggests that neuronal death is limited in infected animals. MEMRI successfully provided both insights into neuronal function and the measurements of brain anatomy.

The toxicity of Mn$^{2+}$ was minimized by a carefully designed MnCl$_2$ administration. We have used a fractionated administration scheme first proposed by [40]. In this scheme, MnCl$_2$ solution was injected daily through i.p. with a small dose for certain days (usually 4-8 days), 4 days for our study. Mice were observed daily after the injection and we did not observe any Mn$^{2+}$ induced toxic clinical signs and symptoms. In totto, we demonstrate that MEMRI can be developed as a biomarker of virus-associated neuropathology. With a thorough understanding of the relationships between MEMRI and neuropathology, monitoring the efficacy of brain therapeutics can be realized for prevention or reversal of virus-associated brain disease.
3.5. References


injury following glial activation by manganese enhanced MRI. J. Neuroimmune Pharmacol. 8, 1027-1036.


metabolic responses to SIV infection in the macaque brain. BMC Neurosci. 10, 63-2202-10-63.


CHAPTER - 4

Generation of a Manganese-Enhanced Magnetic Resonance Imaging (MEMRI)-based NOD/scid-IL-2R\(\gamma_c^{null}\) Mouse Brain Atlas
4.1. Introduction

Advancements in genetic engineering enabled widespread use of transgenic mice for biomedical research. These mice are extensively used in studies of cell, tissue and organism growth, differentiation and disease. Immune deficiency induced by affecting the integrity of the adaptive immune system in NOD/scid-IL-2Rγcnull (NSG) mice permitted the efficient and sustained engraftment of human immunocytes in mice [1,2]. As a result, these mice are used for studies of a broad range of human diseases covering the disciplines of oncology, hematology, infectious disease and regenerative medicine. In particular, our laboratories and others have pursued investigation of human immunodeficiency virus type one (HIV-1) pathobiology including the studies of viral reservoirs and direct tissue injuries including the lung and the central nervous system (CNS) [3-5].

Apropos to studies of end organ diseases associated with HIV-1 infection, magnetic resonance imaging (MRI) has provided critical insights into the mechanisms of virus-induced damage as well as repair following antiretroviral therapy (ART). We posit that such investigations can be substantively improved if specific mouse atlases are generated. Such an atlas could permit broad longitudinal investigation of brain morphology under conditions that mimic aspects of human neurologic disease. Specifically, brain parcellation can automate analyses of structure-wise MRI based metrics (e.g., T1 and T2 relaxation times, diffusion tensor imaging (DTI) measures, metabolites concentrations, pharmacokinetics and pharmacodynamics (PK and PD), and

Reproduced with permission from Sajja BR, Bade AN, Zhou B, Uberti MG, Gorantla S, Gendelman HE, Boska MD, Liu Y; Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγcnull Mouse Brain Atlas; J Neuroimmune Pharmacol. 2015, Nov 10; Copyright Springer
drug biodistribution of magnetically labeled cells and nanomaterials). These works would serve to complement and extend analyses of morphological aberrations seen during progressive infection. Such measures could also be harnessed as biomarkers of disease as well as to determine drug efficacy.

Mouse brain atlases were developed by others [6-13]. Such works were heralded through the need to integrate gene expression with neuroanatomical data and now available as an online public resource [14]. Indeed, recent studies have focused on generating developmental and functional brain atlases [11]. The realization of multi-dimensional (multi-modality and/or multi-parametric) data is notable [10,15].

Acquisition of high resolution data with high signal-to-noise ratios (SNR) involves long MRI scanning times that are difficult in a live mouse. To overcome such difficulties, most researchers have performed \textit{ex vivo} imaging on brain-in-skull or fixed brains and created mouse brain atlases. However, tissue deformations that are common and are linked to the type and duration of brain preparation and fixation methods may affect the atlases generated. Thus, \textit{in vivo} MRI data based atlases can help improving accuracy of brain atlases constructed and can be used for longitudinal analyses of individual mice. \textit{In vivo} atlases on C57BL/6J mouse brain were generated before by others [16,17]. We wished to take this idea a step further in sensitivity through the use of manganese enhanced MRI (MEMRI). Administration of MnCl$_2$ shortens T$_1$ relaxation times in most brain structures, improving signal to noise per unit time and providing excellent contrast between many brain substructures including hippocampus, olfactory bulbs, cerebellum, and cerebral cortical layers as noticed in the present study and previous studies [18,19]. This allows T$_1$-weighted brain MRI at high field strength to be
used to acquire high resolution \textit{in vivo} images while providing enhanced contrast for brain structure identifications. As high-resolution 3D MRI show significant neuroanatomical differences between mouse strains [20], generation of a brain atlas on the same genetic background as used for a disease model serves to enhance accuracy of brain tissue segmentation on MRI. To these ends, the current study developed a 3D \textit{in vivo} MEMRI atlas of NSG mouse.

4.2. Materials and methods

4.2.1. Experimental animals

Nineteen NSG mice (male, weight $= 28.5 \pm 2.4$ grams, age $\sim 1$ year) from a University of Nebraska Medical Center (UNMC) breeding colony were used in study. Animals were maintained in sterile microisolator cages under pathogen-free conditions in accordance with ethical for care of laboratory animals at UNMC set forth by the National Institutes of Health. All procedures were approved by the University’s Institutional Animal Care and Use Committee. Seven human CD34$^+$ hematopoietic stem cells (HSC) reconstituted (humanized) NSG mice (male, weight $= 22.1 \pm 5.3$ grams, age $\sim 1$ year) were scanned using MEMRI to study brain morphology. Additional 6 NSG mice (male, weight $= 30.6 \pm 2.9$ grams, age $\sim 1.5$ years) were included in the study for whole brain T$_2$-weighted MRI data acquisition without MnCl$_2$ administration.

4.2.2. Human CD34$^+$ HSC reconstitution (humanization) of NSG mice

CD34-NSG mice were generated as described in [5]. Human CD34$^+$ HSC were obtained from cord blood (Department of Gynecology and Obstetrics, UNMC) and enriched to
high purity by magnetic bead selection (Miltenyi Biotech Inc., Auburn, CA). The purity of CD34^+ cells was >90% by flow cytometry. Cells were transplanted into newborn mice irradiated at 1Gy using a C9 cobalt 60 source (Picker Corporation). CD34^+ cells were injected intrahepatically at 10^5 cells/mouse in 20 µl of PBS using a 30 gauge needle. The levels of engraftment and number of human cells in peripheral blood were analyzed by flow cytometry (Dash et al., 2011).

4.2.3. MnCl_2 administration

MnCl_2.4H_2O (Sigma-Aldrich, St Louis, MO) was added to saline (0.9% w/v of NaCl solution) to make 120 mM MnCl_2 solution. MnCl_2 was administered at a dose of 125 mg/kg bodyweight using intravenous (i.v.) injections through the tail vein. MnCl_2 was injected using a syringe pump (Harvard Apparatus, MA) at the rate of 125 µL/hour. The dosing scheme was designed based on our experience in MEMRI and several previous studies [19,21-24]. Mice were placed on an electrically heated tail vein injection platform (Braintree Scientific, MA), and were anesthetized by inhalation of isoflurane in 100% oxygen. Breathing rate, cardiac rate and blood oxygen saturation were continuously monitored. Anesthesia level was varied from 0.3% to 1.5% isoflurane to maintain the breathing rate between 40-100 breaths per minute. Immediately after the injection, the mouse was placed on a heating pad in the cage, and its behavior was observed up to four hours to detect the side effects of MnCl_2. The animal was then returned to the animal facility and scanned 24 hours later.

4.2.4. MRI data acquisition
MRI of the 19 NSG mice used for atlas generation were scanned 24 hours after MnCl₂ administration on Bruker Biospec 70/20 (Bruker, Billerica, MA) operating Paravision 4.0 with a custom-built 18 mm birdcage volume coil. The humanized mice that were used to study the effect of humanization on brain volume were scanned using the same MRI scanner operating Paravision 5.1. An 82 mm actively decoupled volume resonator was used for signal transmission and a four-channel phase array coil was used for reception.

Mice were anesthetized by inhalation of isoflurane in 100% oxygen and maintained 40-80 breaths/minute. Three-dimensional T₁-weighted data were acquired using a Rapid Acquisition with Relaxation Enhancement (RARE) sequence with the following parameters: Repetition time (TR) = 400 ms, Effective echo time (TE_{eff}) = 7.2 ms, RARE factor = 4, number of averages = 1, image matrix = 176 × 128 × 128 with 100 μm isotropic pixel size, total scan time = 27 min, anterior-posterior as the readout direction. MRI data were acquired from both normal and humanized mice. Three-dimensional T₂-weighted MRI were obtained from six NSG mice without MnCl₂ administration using the same scanning parameters as for 3D T₁-weighted data except: TR/TE_{eff} = 1500/36 ms, RARE factor = 8, number of averages = 1, total scan time = 1h 55m.

4.2.5. Population averaged MRI mouse brain

All MR brain images were manually brain extracted by separating brain from extracranial tissue using Analyze 10.0v software (www.analyzedirect.com). All brains were registered to median size brain in the group using rigid image registration. Population average brain was created by averaging all registered individual brain images. Then all individual brain
images were iteratively (3 times) affine registered to population average brain and average was updated at each iteration [6]. Finally, nonlinear registration of individual brain images to the average was performed using Large Deformation Diffeomorphic Metric Mapping (LDDMM) to align differences. To minimize the interpolation errors, transformation matrices from individual registrations were combined and applied in one step to each original MRI to generate the final average. All the registration procedures were performed using Diffeomap 1.6v as implemented in DTIStudio software (www.mristudio.org). The final step was to sharpen the boundaries between anatomic features (enhanced brain) by applying the Laplacian as:

\[ g(x, y) = f(x, y) - \nabla^2 f(x, y) \]

where \( g(x, y) \) and \( f(x, y) \) represent enhanced and input images respectively, and \( \nabla^2 \) represents the Laplacian operator.

**4.2.6. Structures delineation and labeling**

Paxinos atlas (Paxinos and Franklin, 2001) and Allen brain digital atlas [14] (http://mouse.brain-map.org/) were followed as reference for identifying and naming different structures on the averaged MEMRI brain images. Amira® 5.21v VSG software (www.amira.com) was used for generating colored labels of brain structures. A three dimensional view with connected cursor was used for accurate identification of various structures.

**4.3. Results**

**4.3.1. Brain structures labeling**
Representative slices from three orthogonal cross-sections of the population averaged MRI are shown in the first column of Fig. 4.1. The second displays the same slices with Laplacian edge enhancement. Improved contrast between structures is realized. The third column shows the manually labeled structures using Amira software. Significant image contrast seen is due to \( \text{MnCl}_2 \) and allowed the identification and delineation of 41 brain structures from the cerebrum (CH), brain stem (BS), cerebellum (CB), fiber tracts (FB), and ventricular systems (VS). All the identified structures’ names are listed in Table 4.1. To the best of our knowledge this is the highest number of structures identified on \textit{in vivo} mouse brain MRI.
Figure 4.1. Columns: **First**: Three orthogonal planes of population average MRI. **Second**: Edge enhancement of images in first column. **Third**: Identified structures on these planes:

- AMY, ac, AON, CA1_CA2_SUB, CA3, CP, Central AMYN, CBXgr, CBXmo, CBwm, AQ, cc, Isocortex, DG-mo, DG-(po+sg), DN, EPI, RFB, FN, GP, HY, IC, IP, LSX, VL, MY, AOB, MOBgl, MOBgr, PIR, opt, PALc, MS, PAG, P, PRT, RMB, SN, TH, V3, V4, STRv (Note: Structures ac, AQ, DN, RFB, FN, IP, V3, and V4 are not presented in the third column of the figure)
### Table 4.1. List of brain regions labeled on MEMRI brain atlas.

<table>
<thead>
<tr>
<th>Region</th>
<th>Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH: Cerebrum</td>
<td>Isocortex: Isocortex</td>
</tr>
</tbody>
</table>
| OLF: Olfactory areas | MOBgl: Main olfactory bulb, glomerular layer  
| | MOBgr: Main olfactory bulb, granule layer  
| | AOB: Accessory olfactory bulb  
| | AON: Anterior olfactory nucleus  
| | PIR: Piriform area |
| HPF: Hippocampal formation | CA1_CA2_SUB: Field CA1 + Field CA2 + Subiculum  
| | CA3: field CA3 of hippocampus  
| | DG-mo: Dentate gyrus_molecular layer  
| | DG-(po+sg): Dentate gyrus_(polymorph layer + granular layer) |
| STR: Striatum | CP: Caudoputamen  
| | STRv: Striatum ventral region  
| | LSX: Lateral septal complex |
| PAL: Pallidum | PALc: Pallidium, caudal region  
| | GP: Globus pallidus  
<p>| | MS: Medial septal nucleus |</p>
<table>
<thead>
<tr>
<th>AMY: Amygdala</th>
<th>AMY: Amygdala</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FB: Fiber tracts</strong></td>
<td></td>
</tr>
<tr>
<td>cc: corpus callosum</td>
<td></td>
</tr>
<tr>
<td>opt: optic tract</td>
<td></td>
</tr>
<tr>
<td>ac: anterior commissure</td>
<td></td>
</tr>
<tr>
<td>RFB: Rest of fiber tracts</td>
<td></td>
</tr>
<tr>
<td><strong>BS: Brain stem</strong></td>
<td></td>
</tr>
<tr>
<td>TH: Thalamus</td>
<td></td>
</tr>
<tr>
<td>EPI: Epithalamus</td>
<td></td>
</tr>
<tr>
<td>HY: Hypothalamus</td>
<td></td>
</tr>
<tr>
<td>IC: Inferior colliculus</td>
<td></td>
</tr>
<tr>
<td>PAG: Periaqueductal gray</td>
<td></td>
</tr>
<tr>
<td>PRT: Pretectal region</td>
<td></td>
</tr>
<tr>
<td>SN: Substantia nigra</td>
<td></td>
</tr>
<tr>
<td>RMB: Rest of midbrain</td>
<td></td>
</tr>
<tr>
<td>P: Pons</td>
<td></td>
</tr>
<tr>
<td>MY: Medulla</td>
<td></td>
</tr>
<tr>
<td><strong>CB: Cerebellum</strong></td>
<td></td>
</tr>
<tr>
<td>CBXmo: Cerebellar cortex, molecular layer</td>
<td></td>
</tr>
<tr>
<td>CBXgr: Cerebellar cortex, granular layer</td>
<td></td>
</tr>
<tr>
<td>CBwm: Cerebellar white matter</td>
<td></td>
</tr>
<tr>
<td>FN: Fastigial nucleus</td>
<td></td>
</tr>
<tr>
<td>IP: Interpose nucleus</td>
<td></td>
</tr>
<tr>
<td>DN: Dentate nucleus</td>
<td></td>
</tr>
<tr>
<td>VS: Ventricular system</td>
<td>VL: Lateral ventricles</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td></td>
<td>V3: Third ventricle</td>
</tr>
<tr>
<td></td>
<td>AQ: Cerebral aqueduct</td>
</tr>
<tr>
<td></td>
<td>V4: Fourth ventricle</td>
</tr>
</tbody>
</table>
4.4. Discussion

We have developed a 3D *in vivo* MEMRI brain atlas for NSG mice containing 41 sub regions. We acknowledge that although this is not the first mouse brain atlas made, it is the sole one constructed by MEMRI for NSG mice analyses. Majority of previous such constructions were made on fixed or post-mortem in situ brains [7,9,10]. However, such prior works may not provide accurate assessment of *in vivo* volumetric and geometrical changes amongst brain regions [16,25]. Indeed, fixation protocols cause alterations in analyses for brain morphology even when MRI data with high resolution and SNR are employed. To this end, the present *in vivo* MEMRI brain atlas allows longitudinal quantitative morphological studies.

There are some advantages of the present approach. *First*, due to MnCl$_2$ ability to selectively reduce local T$_1$ relaxation times, the MEMRI provided increased contrast to noise ratio. *Second*, boundaries between brain structures are enhanced by Laplace Transform image processing. *Third*, specific molecular and granular layers in the brain regions such as the olfactory bulb and cerebellum were identified (Fig. 4.1.). Through such an approach, 41 structures on averaged *in vivo* MRI were delineated and then labeled. This is a significant improvement from prior 3D *in vivo* MRI atlases that enabled only half of the MEMRI-identified brain structures to be processed [16,17]. The developed atlas is made available to researchers through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website ([https://www.nitrc.org/projects/memribrainatlas/](https://www.nitrc.org/projects/memribrainatlas/)).

4.5. Conclusion
An *in vivo* MEMRI-based atlas was generated for brains of NSG mice. Forty-one brain structures were identified to provide a coordinate system for spatial normalization. The atlas provides a database for studies of brain morphology, metabolomics, MR metrics, disease pathobiology, and drug pharmacokinetics in a range of infectious, inflammatory and degenerative disease of the nervous system.
4.6. References


C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience. 135, 1203-1215.


CHAPTER - 5

Potential of N-acetylated-para-aminosalicylic Acid to Accelerate Manganese Enhancement Decline for Long-term MEMRI in Rodent Brain

*: Bade AN and Zhou B. contributed equally to the study
5.1. Introduction

Manganese (Mn$^{2+}$)-enhanced MRI (MEMRI) is a powerful imaging tool to measure rodent neural structure, function and linked pathways [1-3]. It is facilitated by Mn$^{2+}$ entry into neurons that occurs through calcium (Ca$^{2+}$) channels. Here, Mn$^{2+}$ ions accumulate in neurons and are transported along axons. Such ion trafficking reflects neuronal function and networks [1-5]. Mn$^{2+}$ is an excellent T$_1$ shortening paramagnetic contrast agent inducing signal enhancement on T$_1$-weighted (T$_1$-wt) MRI. The retention of Mn$^{2+}$ in brain is prolonged with a half-life ($t_{1/2}$) of 51 to 74 days [5]. Such ion retention allows studies of brain function performed on non-restrained awake rodents [6-10]. In this context, Mn$^{2+}$ administration, sensory stimulation and/or behavioral tests are performed outside the MRI scanner and prior to imaging tests. Studies have shown that brain activities that took place days before imaging tests could be detected using appropriate Mn$^{2+}$ administration schemes such as implanted osmotic pump infusion [9,10]. The long Mn$^{2+}$ brain retention time also enables the monitoring of Mn$^{2+}$ axonal transportation for studies evaluating neural pathways[11-13]. MEMRI is also proven a valuable tool in neurodegenerative disorder studies using rodents [14-25]. However and despite such advantages, its application is limited in the longitudinal follow-up of neurodegenerative disorders due to the prolonged washout time of Mn$^{2+}$. During the time span of the studies that can be as long as weeks and even months, repeated Mn$^{2+}$ administration is usually necessary to keep brain Mn$^{2+}$ concentration consistent among imaging sessions. This requires carefully designed dosing if imaging needs to be performed before the residual

Mn$^{2+}$ from preceding administrations is eliminated. Infusion using commercially available osmotic pumps may keep brain Mn$^{2+}$ concentration consistent for up to six weeks (Alzet, Cupertino, CA), which is usually not sufficient in time to evaluate the progression of neurodegenerative disorders in rodents. Moreover, repeated or continuous Mn$^{2+}$ administration can cause secondary toxicities [26]. One solution is to accelerate Mn$^{2+}$ brain elimination after each MEMRI tests and as such limit the effect of residual Mn$^{2+}$ on the MEMRI evaluation. Accelerated Mn$^{2+}$ washouts may also serve to minimize Mn$^{2+}$ toxicity.

With this in mind, we tested whether N-acetylated-para-aminosalicylic acid (AcPAS) could accelerate Mn$^{2+}$ elimination from brain. AcPAS, an N-acetylated metabolite of para-aminosalicylic acid (PAS), was previously used to treat human manganism, a disorder which parallels several of the clinical features of Parkinson’s disease [27]. Treatment of Mn$^{2+}$ intoxication is linked to PAS chelation [28,29]. Chelation is the binding of organic compounds and metal ions. The brain distribution, metabolism, and time-concentration relationships of PAS and its major metabolite, AcPAS, were previously investigated [30,31]. The results demonstrated that AcPAS chelates Mn$^{2+}$. AcPAS has higher brain concentration and possesses a longer $t_{1/2}$ than PAS. Herein we demonstrate that AcPAS can be employed to improve the MEMRI utility by permitting serial brain measurements in health and disease.

5.2. Materials and Methods

5.2.1. Study Design
C57BL/6 mice were used in this study. Mice were housed in the University of Nebraska Medical Center (UNMC) laboratory animal facility according to the American Animal Association and Laboratory Animal Care guidance. All procedures were approved by the Institutional Animal Care and Use Committee at UNMC. The kinetics of AcPAS in brain tissue and plasma was first studied using high-performance liquid chromatography (HPLC) using one group of mice. Another group of mice was first administrated MnCl$_2$ via the intraperitoneal (i.p.) route, followed with PBS (n = 3), low dose (n = 3, 100 mg/kg), medium dose (n = 3, 150 mg/kg) and high dose AcPAS (n = 3, 200 mg/kg) three times daily for two weeks. The doses and administration scheme were designed based on the previous PK studies of AcPAS [30,31]. MRI was performed one day after the MnCl$_2$ administration followed by AcPAS/PBS treatment. Two more MRI scans were performed at one and weeks of AcPAS/PBS treatment. After the last MRI, the mice were immediately euthanized for inductively coupled plasma mass spectrometry (ICP/MS) analysis of brain Mn$^{2+}$ concentrations. The timeline of the study design is shown in Fig. 5.1. Three animals were randomly selected from the above 12 AcPAS/PBS-treated mice and were scanned before any drug administration for baseline measurements of MRI and ICP/MS.

5.2.2. AcPAS Synthesis

AcPAS was synthesized by a modified procedure [32]. Briefly, p-aminosalicylic acid (0.33 mol), was dissolved in 100 ml of 2 M hydrochloric acid and stirred with sodium acetate (0.33 mol) in water at 0° C. The reaction mixture was stirred overnight with 50 ml of acetic anhydride at room temperature. The brown precipitate obtained was filtered,
washed, dried and dissolved in 0.1M sodium hydroxide then stirred overnight. The resulting solution was adjusted to pH 2 with HCl. The product was extracted with ethyl acetate (3 × 75 ml) and the extracts were dried over anhydrous sodium sulphate. The solid residue was washed with hexane to produce 52 % yield of pure AcPAS. The identity of AcPAS was confirmed by NMR with > 99 % purity.

5.2.3. High performance liquid chromatography (HPLC)

AcPAS (200 mg/kg) was administered to mice (n = 9) by i.p. injection. Plasma was collected at 0.5, 1, 2, 6 and 12 hours. Mouse peripheral blood samples (100 µl) were collected from submandibular vein (cheek bleed) by using sterile lancets (MEDIpoint, Inc., Mineola, NY) in EDTA coated tubes. Plasma was separated by centrifugation of blood samples at 1,800 rpm for 8 min at 4°C within 1 h of sample collection and stored at -80°C until analysis. Brain tissues (cortex, thalamus, olfactory bulb) of same group of mice administered with the same dose of AcPAS were collected at 6, 8 and 12 (n = 3 for each time point) hours after administration. AcPAS from plasma and tissues were extracted using acetonitrile. AcPAS was quantified by HPLC according to the method of Sugamori et al. [33]. Briefly, extracted plasma or brain samples were injected in duplicate (20µl) onto a Shimadzu HPLC (Shimadzu Scientific Instruments, Columbia, MD) containing a Synergi 4µ Hydro-RP column (4.6 × 150 mm) (Phenomenex, Torrance, CA) and extruded using an isocratic mobile phase of 7% acetonitrile/1% acetic acid/0.1% triethylamine at a flow rate of 1.6 ml/min. AcPAS were detected at a wavelength of 270 nm and quantitated by peak comparisons to a standard curve (0.05-50 µg/ml).
5.2.4. MnCl₂ and AcPAS treatment

MnCl₂·4H₂O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl₂ solution. MnCl₂ solution was delivered i.p. at a dose of 60 mg/kg consecutively four times at 24 hour intervals. The fractional administration scheme was designed to minimize Mn²⁺ toxicity [34]. After injection, the mice were observed daily to monitor potential Mn²⁺ toxicities. AcPAS injection started one day after the MnCl₂ administration. AcPAS (1 mg) was mixed with 1 μl DMSO in a glass container. More (1 – 2 μl) DMSO was added until the compound was dissolved. Physiological saline (0.9% NaCl) was added to dilute the solution to 20 mg/ml AcPAS. The solution became a suspension with addition of saline. It was then stored at 4 °C. Before each injection, the suspension was thoroughly mixed by shaking. AcPAS was injected i.p. 3 times per day at eight-hour intervals for two weeks. Before each drug injection, the animal was observed for any abnormal changes in behavior, hair coat, facial expression, ambulation and body weight.

5.2.5. MRI

MRI was performed on a Bruker Bioscan 7 Tesla/21 cm MRI (Bruker, Billerica, MA) operating Paravision 5.1 with a 82 mm quadrature volume resonator and a 4-channel phased array receive coil. Mice were anesthetized by inhalation of isoflurane in 100% oxygen and maintained 40-80 breaths/minute. Mice were scanned using T₁ mapping (fast spin echo with variable TR from 0.4 s to 10 s, TE = 7.0 ms, 12 coronal slices, slice thickness = 0.5 mm, in-plane resolution = 0.156 × 0.156 mm², FOV = 20 × 20 mm²) and three-dimensional T₁W MRI (gradient recalled echo, TR/TE = 20/4.5 ms, flip angle =
To reduce the influence of the inhomogeneous signal reception on the T₁W images by the phased array surface coil, N3 field inhomogeneity correction [35] was first performed on each image using MIPAV (CIT, NIH). The brain volumes in the T₁W images were extracted using an in-house Matlab program [36] based on the level sets method. The brain images were then registered to the MRI-based mouse brain atlas downloaded from the Laboratory of Neuro Imaging (LONI) at the University of Southern California using affine transformation first, and then nonlinear transformation (DiffeoMap, John Hopkins University, Baltimore, MD).

To use signal changes in high resolution T₁W MRI to represent Mn²⁺ accumulation, signal differences need to be scaled to absolute changes in T₁ values. This is achieved by calibrating the baseline and post Mn²⁺ injection T₁W images using T₁ values. The T₁ maps were first generated using an in-house Interactive Data Language (IDL) version 8.2 (Exelis Visual Information Solutions, Boulder, Colorado) program from the data acquired by T₁ mapping sequence. Regions of interest (ROI) were then placed on relatively uniform tissue regions including frontal cortex and caudate on T₁ maps and T₁W images. The baseline and post Mn²⁺ injection longitudinal relaxivity and T₁W signal intensity in the ROIs were measured. We assumed that the effect of the system variation is a constant C (calibration factor) and set system parameter of the post-manganese session as 1, then the measured baseline signal (designated as $S_{bl}^C$) is $S_{bl}^C = CS_{bl}$, where $S_{bl}$ is the true (calibrated) baseline signal. The calibration factor was calculated as $C = (S_{bl}^C / S_{Mn}) \times (R_{1Mn} / R_{1bl})$, where $R_{1bl}$ and $R_{1Mn}$ are baseline and post Mn²⁺
injection longitudinal relaxivities, respectively; $S_{\text{Mn}}$ is post Mn$^{2+}$ T$_1$W signal intensity. The calibration factor was then applied to the baseline T$_1$W image to calculate the true baseline image: $S_{bl} = S_{bl}^{C} / C$.

The Mn$^{2+}$ induced T$_1$W signal enhancement was calculated by: $(S_{\text{Mn}} - S_{\text{bl}}) / S_{\text{bl}}$. This equation was derived by ignoring the T$_2^*$ effect in the MRI signal generated using a spoiled gradient recalled echo, and replacing the exponential of $(-\text{TR}/T_1)$ with the first two terms of its Taylor expansion. These operations were appropriate as a previous study has shown that Mn$^{2+}$ induced T$_2$ change is small compared to T$_1$ reduction [37], and $(-\text{TR}/T_1)$ is small (TR = 20 ms and T$_1 > 800$ ms in most brain regions). Using the LONI brain atlas, enhancement on brain regions/sub-regions was calculated. A region-by-region comparison was performed between AcPAS treated groups and PBS controls using Student’s t-test at each time point.

5.2.6. ICP/MS Analyses

Known weights of thawed brain regions (cortex, thalamus, olfactory bulb), collected from the animals were decomposed by wet-ashing in vials with six volumes of concentrated nitric acid followed by microwave (MARS, CEM Corp., Matthews, NC) heating at 200 °C. Total manganese concentrations were determined by ICP-MS (NexION 300Q, PerkinElmer, MA, USA).

5.2.7. Statistical Analysis

Student’s t-tests were used for all statistical analyses. The significance level was 0.05.
5.3. Results

5.3.1. AcPAS plasma and brain levels

AcPAS plasma and brain concentrations are shown in Figure 5.2. AcPAS was reduced in concentration at 2 hours from > 400 to < 23 ng/ml in plasma. The reduction reached eight ng/ml at 12 hours. AcPAS increased in the cortex, thalamus and olfactory bulbs with time after six hours. The highest AcPAS tissue concentration was in olfactory bulbs with less drug in the thalamus and cortex (Fig. 5.2).

5.3.2. MRI

Mn$^{2+}$ induced enhancement on T$_1$W MRI was seen after 24 hours of MnCl$_2$ injection (Fig 5.3.A-a). Mn$^{2+}$ induced signal enhancement on T$_1$W MR images was seen in the hippocampus, cerebellum and olfactory bulbs (Fig 5.3.A-a) [3,4]. The MR images one week after MnCl$_2$ injection are illustrated in Fig 5.3.A-b with the top panel the PBS and bottom high dose AcPAS treated mice. The signal intensity was decreased at 1 week in both groups. Compared to PBS controls, decreased signal intensities were seen in AcPAS treated mice. This was most notable in the hippocampus and cortex. After 2 weeks of treatment, AcPAS treated mice (Fig 5.3.A-c, top panel) showed greater decreased signal intensity than PBS controls (Fig 5.3.A-c, bottom panel) throughout the multiple brain regions.

5.3.3. Mn$^{2+}$ enhancement

The enhancement maps are shown in Fig 5.3.B, and quantified region-specific enhancement results are listed in Table 1. After 24 hours, Mn$^{2+}$ induced enhancement is
throughout the whole brain (96% enhancement) with the relatively high enhancement on olfactory system (Olf, 97%), lateral olfactory tract (lo, 136%), optic chiasm (ox, 98%), hippocampus (HIP, 97%), hypothalamus (Hy, 98%), interpeduncular nucleus (IP, 97%), and cerebellum (Cb, 96%) regions (Fig 5.3.B-a, 1^{st} column in Table 5.1). The brain region abbreviations follow the conventions in the Paxinos and Franklin mouse brain atlas. Natural enhancement decline was clearly seen in PBS controls after one week from 85-136% to 30-62% (Fig 5.3.B-b top panel, 2^{nd} column in Table 5.1). Mice treated with low (100 mg/kg) and medium (150 mg/kg) doses did not show significant difference compared to PBS controls (data not shown). The enhancement in high dose (200 mg/kg) AcPAS treated mice was lower than in PBS animals (Fig 5.3.B-b). The enhancement difference was significant (p < 0.05) on substantia nigra (SN), corpus callosum (cc), thalamus (Th), hippocampus (HIP) and olfactory bulb (Olf) regions (3^{rd} column in Table 5.1).

The enhancement decreased significantly after two weeks in PBS controls to 22-59% (Fig 5.3.B-c top panel, 4^{th} column in Table 5.1). After two-weeks, medium dose (150 mg/kg) AcPAS treated mice showed significantly decreased enhancement compared to PBS controls on fornix (f) and optic chiasm (ox) (5^{th} column in Table 5.1). In high dose (200 mg/kg) AcPAS treated mice, a number of brain regions showed significantly decreased enhancement including the caudate putamen (CPu), basal ganglia (BG) and internal capsule (ic) (6^{th} column in Table 5.1). The whole brain enhancement in high dose (200 mg/kg) AcPAS treated mice was also significantly less than in PBS controls. The brain regions with significantly reduced enhancement in high dose (200 mg/kg) AcPAS treated mice are shown in Fig 5.4.
Manganese concentrations measured by ICP/MS in mouse brains at 24 hours after MnCl$_2$ administration were 183±25.8 parts per billion (ppb) in cortex, 280±29.2 ppb in thalamus, 203±14.8 ppb in hippocampus, and 507±164 ppb in olfactory bulbs. The concentrations were presented as mean±SEM. The concentrations decreased in PBS treated controls after 2 weeks to 61.6±1.45, 71.7±2.96, 57.6±7.61 and 170±21.4 ppb in cortex, thalamus, hippocampus and olfactory bulbs, respectively. The concentrations in high dose AcPAS treated mice at two weeks were 74.3±9.29, 85.3±22.2, 72.8±26.6, and 119±19.4 ppb in cortex, thalamus, hippocampus and olfactory bulbs, respectively. No significant difference was found between saline controls and AcPAS treated mice (p > 0.1, data not shown).

5.4. Discussion

This study investigated the abilities of AcPAS treatment to affect repeated MEMRI measurements of brain structure and function. We demonstrate that, even though AcPAS did not lead to accelerated Mn$^{2+}$ brain elimination, it suppressed significantly Mn$^{2+}$-induced MRI enhancement after about two weeks treatment when using the high dose (200mg/kg × 3 daily). Based on these findings, AcPAS has the potential to enable repeated MEMRI measurements and minimize Mn$^{2+}$ toxicity.

AcPAS can be rapidly eliminated from blood within an hour. As soon as six hours after the injection, AcPAS has entered the brain and its concentration increased over the next six hours. This finding is in agreement with a previous PK study of PAS and AcPAS (32). These findings suggested that, to achieve sufficient brain concentrations, AcPAS must be administrated by multiple injections over a day or by continuous infusion.
Therefore the dosing and administration scheme were designed based on these findings and previous PK and PD studies of AcPAS (32). The accelerated Mn^{2+} washout induced by AcPAS is different among brain regions. HIP, TH, CPu are among the regions of fastest washout. This is in the agreement of a previous study showing high AcPAS concentration in these regions [30].

The ICP/MS data suggested that AcPAS failed to speed the elimination of Mn^{2+}. However, MRI results showed faster enhancement decline in AcPAS treated mice compared to PBS controls at high dose. The discordant results can be explained as follows. The chelation of paramagnetic Mn^{2+} by AcPAS limits its interaction with water molecules, and thus causes the decrease in Mn^{2+} induced signal enhancement. On the other hand, the high tissue affinity and long $t_{1/2}$ of AcPAS limit the elimination of chelated Mn^{2+} from brain.

The study showed that an average 17% enhancement remains in brain after 2-week high dose AcPAS treatment. Further experiments are necessary to determine the time to complete elimination of enhancement. Nevertheless, AcPAS provides an option for serial studies with a shorter time interval compared to the inherent Mn^{2+} washout of 17-26 weeks [5]. We did not observe any side-effects of AcPAS in the animals. It is quite possible that higher dose (> 200 mg/kg) AcPAS treatments would eliminate the enhancement more quickly than the highest dose used in this study.

A more comprehensive study is being planned, in which a second MEMRI experiment will be performed after AcPAS treatment to ensure the enhancement efficiency still holds, and Mn^{2+} update and retention by neurons are not affected after the AcPAS treatment. The study will prove the feasibility of using AcPAS for repeated
MEMRI. We do not expect AcPAS treatment causes brain water relaxivity changes, because AcPAS is an organic compound cleared from brain with a half-life of 100-200 minutes [30], and is diamagnetic. To prove the hypothesis, one more group of mice will be added in the planned study that will receive AcPAS treatment and MRI scans but not MnCl₂ injection. This group is to detect any effect on brain water relaxivity caused by AcPAS treatment.

PAS [4-amino-2-hydroxybenzoic acid (Paser); CAS number, 65-49-6] has been well known as an antituberculosis drug since the 1950s [38]. Its side effects on humans have been investigated [38]. The toxicity of its tissue metabolite - AcPAS needs to be further studied for use in MEMRI. In this study, no abnormal changes in behavior, hair coat, facial expression, ambulation and body weight were found in the animals. Even though AcPAS does not accelerate the removal of Mn²⁺ from brain, its chelation of Mn²⁺ is believed to minimize Mn²⁺ toxicity. If AcPAS is to be used in neurological disease studies using rodent models, its compatibility with the studies needs to be considered to assure its administration will not inadvertently affecting key physiological/disease-related parameters. In conclusion, we showed that, while AcPAS does not eliminate Mn²⁺ from brain, it accelerates Mn²⁺ induced enhancement decline in MRI. The results suggested the potential to use AcPAS for serial MEMRI measurements of voltage-gated calcium channel activity and morphology in rodent brains. In future studies, we will follow the animals longer to study the long-term effects of AcPAS on Mn²⁺ elimination and parallel MEMRI test results.
Figure 5.1. Study design. Mice were first administrated with MnCl\textsubscript{2}, followed with PBS (\(n=3\)), low dose (\(n=3, 100\) mg/kg), medium dose (\(n=3, 150\) mg/kg) or high dose AcPAS (\(n=3, 200\) mg/kg) for two weeks. MRI was performed on the mice at one and two weeks after MnCl\textsubscript{2} administration. After the second MRI, the mice were immediately euthanized for ICP/MS analysis of brain Mn\textsuperscript{2+} concentrations.
Figure 5.2. AcPAS concentrations measured by HPLC in plasma (blue line) and in the brain regions (red lines). The concentrations in plasma were measured in ng/ml (left vertical axis), and in brain were measured in ng/mg (right vertical axis). The error bar at each time point shows the mean standard error of the measurement.
Figure 5.3. (A) MRI data. (a) Averaged MRI of mice (n = 9) at 24 hours after MnCl$_2$ administration. (b) Averaged MRI of PBS controls (n = 3, top panel) and high dose AcPAS treated mice (n = 3, bottom panel) at one week after MnCl$_2$ administration. (c) Averaged MRI of PBS controls (n = 3, top panel) and high dose AcPAS treated mice (n = 3, bottom panel) at two weeks after MnCl$_2$ administration. (B) Manganese enhancement maps corresponding to Figure 3A.
Figure 5.4. Brain regions with significantly less enhancement in mice after one (A) and two (B) weeks high dose AcPAS treatment compared to in PBS controls. The regions are shown in coronal slices, whose locations are indicated using red lines on the sagittal slices in the leftmost column.
Table 5.1. Brain regions with significantly decreased enhancement in mice after 1 and 2 weeks high dose AcPAS treatment compared to in PBS controls.

Enhancement data are presented as percentage and in Mean ± Standard deviation.

*: \( p < 0.1 \); **: \( p < 0.05 \)

<table>
<thead>
<tr>
<th>Region</th>
<th>0 week</th>
<th>1 week</th>
<th>2 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All (%)</td>
<td>PBS (%)</td>
<td>High Dose (%)</td>
</tr>
<tr>
<td>f</td>
<td>89±13</td>
<td>35±7</td>
<td>7±13</td>
</tr>
<tr>
<td>Ox</td>
<td>98±14</td>
<td>37±11</td>
<td>37±7</td>
</tr>
<tr>
<td>Cb</td>
<td>96±13</td>
<td>39±7</td>
<td>32±7</td>
</tr>
<tr>
<td>SN</td>
<td>91±12</td>
<td>40±4</td>
<td>30±7**</td>
</tr>
<tr>
<td>IP</td>
<td>97±14</td>
<td>50±3</td>
<td>37±11</td>
</tr>
<tr>
<td>cc</td>
<td>87±12</td>
<td>37±4</td>
<td>27±6**</td>
</tr>
<tr>
<td>Hy</td>
<td>98±13</td>
<td>41±5</td>
<td>37±5</td>
</tr>
<tr>
<td>Th</td>
<td>89±13</td>
<td>38±4</td>
<td>28±5**</td>
</tr>
<tr>
<td>CP</td>
<td>90±12</td>
<td>40±4</td>
<td>30±8*</td>
</tr>
<tr>
<td>BG</td>
<td>95±13</td>
<td>42±4</td>
<td>33±8*</td>
</tr>
<tr>
<td>HIP</td>
<td>97±13</td>
<td>42±4</td>
<td>33±6**</td>
</tr>
<tr>
<td>lo</td>
<td>136±24</td>
<td>62±20</td>
<td>60±11</td>
</tr>
<tr>
<td>Off</td>
<td>97±13</td>
<td>45±8</td>
<td>31±8**</td>
</tr>
<tr>
<td>Cx</td>
<td>95±14</td>
<td>40±8</td>
<td>32±6*</td>
</tr>
<tr>
<td>ic</td>
<td>85±16</td>
<td>30±4</td>
<td>24±7</td>
</tr>
<tr>
<td>Fr</td>
<td>95±17</td>
<td>38±6</td>
<td>32±4*</td>
</tr>
<tr>
<td>Br</td>
<td>96±16</td>
<td>36±9</td>
<td>29±7</td>
</tr>
</tbody>
</table>
5.5. References


CHAPTER – 6
Summary, Limitations, and Future Directions
Translational animal models of brain disorders remain essential for thorough understanding of the patho-biological mechanisms, as comprehensive research cannot be done in controlled and reproducible manner on humans. Research directed at morphological, pathophysiological mechanisms and functional activities of the CNS can be realized through imaging systems in vivo. A significant literature now demonstrates the importance and utility of MRI towards unraveling the complex neural system, healthy or diseased. MRI is a non-invasive and versatile imaging tool. It allows longitudinal, three-dimensional assessment of tissue anatomy, pathophysiology, function and metabolism. Due to these properties MRI has achieved widespread success in experimental neuroscience studies. Yet, there is a room for improvement in MRI specificity and sensitivity, and this can be achieved by using contrast agents, especially Mn$^{2+}$.

MEMRI opens the great opportunity to study complex paradigms in freely behaving animals. By taking the advantage of chemical and biological properties of Mn$^{2+}$ in living organisms, MEMRI has been successfully applied in the studies of several neurological diseases using animal models, such as stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, and other brain disorders to assess detailed information about neuronal activity, morphology and neuronal tracts as well as rate of axonal transport. Mn$^{2+}$ is toxic, however, MEMRI reveals new patho-biological information that might be otherwise difficult to gain. Properly planned administration of Mn$^{2+}$ and close monitoring of animals after administration is required to avoid toxicity and pain to animals. Although previous studies highlight the potential of MEMRI for brain imaging, the limitations still exist concerning the use of Mn$^{2+}$ in living animals. The development
of MEMRI applications in neuroscience research are at the beginning level. Therefore, development of methods of MEMRI for experimental studies remains essential for diagnostic findings as well as development of therapeutic strategies.

In the first study (Chapter - 2), we investigated role of glia and neurons in MEMRI signal enhancement during inflammation. Unlike other contrast agents such as gadolinium, iron oxide, and iron platinum Mn$^{2+}$ can provide unique intracellular insights about brain pathophysiology. Nonetheless, a critical question that remained poorly understood was the brain cells that serve as sources for the MEMRI signal enhancement during inflammation. In this study, we investigated MEMRI’s abilities to detect glial (astrocyte and microglia) and neuronal activation signals following treatment with known inflammatory inducing agents. The idea was to distinguish between gliosis (glial activation) and neuronal injury for the MEMRI signal and as such use the agent as a marker for neural activity in inflammatory and degenerative disease. This work demonstrated that cytokine-induced glial activation facilitates neuronal uptake of Mn$^{2+}$ in vitro. Glial Mn$^{2+}$ content was not associated with glial activation. After in vitro conformation, we validated our hypothesis in vivo. MEMRI was performed on mice injected with lipopolysaccharide by IC route. MEMRI signal enhancement was associated with increased neuronal activity. In conclusion, results supported the notion that MEMRI reflects neuronal excitotoxicity and impairment that can occur through a range of insults that include neuroinflammation and MEMRI signal enhancement in the CNS is induced by astrocytic activation by stimulating neuronal Mn$^{2+}$ uptake.

In the second study (Chapter - 3), we evaluated the efficacy of MEMRI in diagnosing the brain pathology in an animal model of neurodegenerative disease,
Progressive human immunodeficiency viral (HIV) infection commonly leads to a constellation of cognitive, motor and behavioral impairments. These are collectively termed HIV-associated neurocognitive disorders (HAND). While antiretroviral therapy (ART) reduces HAND severity, it does not affect disease prevalence. Despite decades of research there remain no biomarkers for HAND and all potential co-morbid conditions must first be excluded for a diagnosis to be made. To this end, we now report that MEMRI can reflect brain region specific HIV-1-induced neuropathology in chronically virus-infected NOD/scid-IL-2Rγcnull humanized mice. MEMRI diagnostics mirrors the abilities of Mn^{2+} to enter and accumulate in affected neurons during disease. T_1 relaxivity and its weighted signal intensity are proportional to Mn^{2+} activities in neurons. In 16-week virus-infected humanized mice, altered MEMRI signal enhancement was easily observed in affected brain regions. These included, but were not limited to, the hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, substantia nigra and cerebellum. MEMRI signal was coordinated with levels of HIV-1 infection, neuroinflammation (astro- and micro- gliosis), and neuronal injury. MEMRI accurately demonstrates the complexities of HIV-1 associated neuropathology in rodents that reflects, in measure, the clinical manifestations of neuroAIDS as it is seen in a human host.

In the third study (Chapter – 4), our successful collaboration with Dr. Sajja BR (Associate Professor, Department of Radiology, UNMC, Omaha, NE) led to generation of a MEMRI-based NOD/scid-IL-2Rγcnull (NSG) mouse brain atlas. Strain specific mouse brain MRI atlases provide coordinate space linked anatomical registration. This allows longitudinal quantitative analyses of neuroanatomical volumes and imaging metrics for
assessing the role played by aging and disease to the central nervous system. As NSG mice allow human cell transplantation to study human disease, these animals are used to assess brain morphology. MEMRI improves contrasts amongst brain components and as such can greatly help identifying a broad number of structures on MRI. To this end, NSG adult mouse brains were imaged *in vivo* on a 7.0 Tesla MR scanner at an isotropic resolution of 100 µm. A population averaged brain of 19 mice was generated using an iterative alignment algorithm. MEMRI provided sufficient contrast permitting 41 brain structures to be manually labeled. The developed atlas is made available to researchers through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website (https://www.nitrc.org/projects/memribrainatlas/).

In the fourth study (Chapter – 5), we evaluated the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate Mn$^{2+}$ elimination from rodent brain. The brain retention of Mn$^{2+}$ is relatively long with a half-life ($t_{1/2}$) of 51 to 74 days causing a slow decline of MRI signal enhancement following Mn$^{2+}$ administration. Such slow decline limits using repeated MEMRI to follow the central nervous system longitudinally in weeks or months. This is because residual Mn$^{2+}$ from proceeding administrations can confound the interpretation of imaging results. To the best of our knowledge, no method exists to accelerate the decline of the Mn$^{2+}$ induced MRI enhancement for repeated MEMRI tests. We investigated whether AcPAS, a chelator of Mn$^{2+}$, could affect the decline of Mn$^{2+}$ induced MRI enhancement in brain thus enabling repeated MEMRI, and as a consequence broadens the utility of MEMRI tests. Two-week treatment with AcPAS (200 mg/kg/dose × 3 daily) accelerated the decline of Mn$^{2+}$ induced enhancement in MRI. (In the whole brain on average the enhancement declined 83% in AcPAS treated
mice, while in PBS controls the decline was 73%. We posit that AcPAS could enhance MEMRI utility for evaluating brain biology in small animals. Further study needed for detailed understanding.

In general, major disadvantage of MEMRI is the toxicity associated with Mn$^{2+}$, which restricted its clinical transformation. As obtained MEMRI contrast is directly related to accumulation of Mn$^{2+}$ in excitable cells in activity dependent manner, MEMRI has been successfully used to study neuronal activation. However, difference in Mn$^{2+}$ influx and efflux rates (long half-life in brain) or long clearance time allowed to produce only static activation maps and do not allow to inform about temporal or rapid changes in neuronal activity (Silva et al. 2012). Also, it remains to be investigated whether MEMRI detects neuronal deactivation (Silva et al. 2012). We have demonstrated that MEMRI visualizes reactive astrogliosis (increase in signal intensity) and neuronal loss (decrease in signal intensity; ongoing study in the lab, data not shown in this thesis). But limitation is that one of the dominating cellular mechanisms offsets other mechanism to determine the MEMRI results. MEMRI is still not sensitive enough to detect gliosis and neuronal loss at the same time. Also, threshold level of cellular activity for generating MEMRI signal is not studied yet.

In all the studies of this thesis, we have measured and compared $T_1$ signal intensities on three-dimensional (3D) high-resolution ($\leq 100$ μm pixel size) $T_1$-wt images for healthy and diseased animals. $T_1$ values were also measured using multi-slice MRI with lower in-plane resolution. MRI scanner system variation was then estimated using the $T_1$ values and $T_1$-wt signal. The acquired $T_1$-wt images were then calibrated. Detailed process of the image calibration is described in chapter - 3 of this thesis. We are
now developing a fast $T_1$ mapping sequence to directly measure brain $T_1$ values by a 3D high-resolution fashion. This method will provide more accurate results on brain Mn$^{2+}$ uptake and accumulation.

There are extensive possibilities for future applications of MEMRI in translational neuroscience research. The possibility of longitudinal studies enable the measurement of functional changes in CNS after pharmacological interventions as well as therapeutic treatment. Integration of MEMRI with multiple imaging modalities will overcome the limitations of previous single parametric approach and therefore, will establish a comprehensive study to understand neurobiological mechanisms underlying normal and abnormal functions.